



 SECTION E
MORBIDITY &
HOSPITALIZATION





CONTENTS

- 373 E.1 First Admissions per 1,000 Patient Years: All ESRD Patients
period prevalent patients, 1999
- 374 E.2 First Admissions per 1,000 Patient Years: All Dialysis Patients
period prevalent patients, 1999
- 375 E.3 First Admissions per 1,000 Patient Years: All Hemodialysis Patients
period prevalent patients, 1999
- 376 E.4 First Admissions per 1,000 Patient Years: All CAPD/CCPD Patients
period prevalent patients, 1999
- 377 E.5 First Admissions per 1,000 Patient Years: All Transplant Patients
period prevalent patients, 1999; first three years after transplant
- 378 E.6 First Admission Standardized Hospitalization Ratios
by state, all period prevalent dialysis patients
- 379 E.7 Total Admissions per 1,000 Patient Years: All ESRD Patients, 1999
period prevalent patients
- 380 E.8 Total Admissions per 1,000 Patient Years: All ESRD Patients, 1997-1999
period prevalent patients
- 381 E.9 Total Admissions per 1,000 Patient Years: All Dialysis Patients, 1999
period prevalent patients
- 382 E.10 Total Admissions per 1,000 Patient Years: All Dialysis Patients, 1997-1999
period prevalent patients
- 383 E.11 Total Admissions per 1,000 Patient Years: All Hemodialysis Patients, 1999
period prevalent patients
- 384 E.12 Total Admissions per 1,000 Patient Years: All Hemodialysis Patients, 1997-1999
period prevalent patients
- 385 E.13 Total Admissions per 1,000 Patient Years: All CAPD/CCPD Patients, 1999
period prevalent patients
- 386 E.14 Total Admissions per 1,000 Patient Years: All CAPD/CCPD Patients, 1997-1999
period prevalent patients
- 387 E.15 Total Admissions per 1,000 Patient Years: All Transplant Patients, 1999
period prevalent patients; first three years after transplant
- 388 E.16 Total Admissions per 1,000 Patient Years: All Transplant Patients, 1997-1999
period prevalent patients; first three years after transplant
- 389 E.17 Hospital Days per Patient Year: All ESRD Patients, 1999
period prevalent patients
- 390 E.18 Hospital Days per Patient Year: All ESRD Patients, 1997-1999
period prevalent patients
- 391 E.19 Hospital Days per Patient Year: All Dialysis Patients, 1999
period prevalent patients



- 392 E.20 Hospital Days per Patient Year: All Dialysis Patients, 1997-1999
period prevalent patients
- 393 E.21 Hospital Days per Patient Year: All Hemodialysis Patients, 1999
period prevalent patients
- 394 E.22 Hospital Days per Patient Year: All Hemodialysis Patients, 1997-1999
period prevalent patients
- 395 E.23 Hospital Days per Patient Year: All CAPD/CCPD Patients, 1999
period prevalent patients
- 396 E.24 Hospital Days per Patient Year: All CAPD/CCPD Patients, 1997-1999
period prevalent patients
- 397 E.25 Hospital Days per Patient Year: All Transplant Patients, 1999
period prevalent patients; first three years after transplant
- 398 E.26 Hospital Days per Patient Year: All Transplant Patients, 1997-1999
period prevalent patients; first three years after transplant
- 399 E.27 Total Hospital Discharges by General Diagnostic Related Group
period prevalent patients, 1997-1999

Table E.1
First Admissions per 1,000 Patient Years: All ESRD Patients
period prevalent patients, 1999

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	1,403	1,654	1,594	1,330	1,446	1,752	2,106	1,866	1,562	2,011	1,524	2,050	1,730	1,446	1,797
20-29	1,248	1,490	1,347	1,090	1,320	1,449	1,754	1,529	1,265	1,566	1,346	1,645	1,517	1,187	1,450
30-39	1,236	1,423	1,189	969	1,271	1,293	1,590	1,432	1,150	1,379	1,257	1,502	1,287	1,058	1,314
40-49	1,219	1,290	1,227	908	1,231	1,394	1,510	1,372	1,091	1,430	1,285	1,394	1,287	980	1,312
50-59	1,262	1,199	1,248	986	1,229	1,521	1,434	1,356	1,116	1,459	1,368	1,322	1,304	1,043	1,336
60-64	1,368	1,222	1,340	1,000	1,301	1,575	1,395	1,353	1,022	1,461	1,466	1,324	1,347	1,012	1,386
65-69	1,426	1,249	1,350	1,012	1,346	1,551	1,390	1,324	1,040	1,456	1,493	1,339	1,333	1,027	1,410
70-79	1,520	1,306	1,354	1,022	1,437	1,622	1,505	1,379	1,027	1,542	1,574	1,440	1,371	1,025	1,499
80+	1,715	1,529	1,526	1,042	1,622	1,845	1,715	1,517	1,060	1,745	1,784	1,657	1,519	1,052	1,694
All	1,374	1,267	1,289	998	1,324	1,559	1,467	1,364	1,054	1,495	1,462	1,385	1,331	1,027	1,413
HYPERTENSION															
0-19	763	893	956	669	848	954	1,164	1,127	786	1,051	851	994	1,041	786	934
20-29	703	767	866	583	748	862	982	1,002	676	936	769	831	943	611	810
30-39	741	864	886	588	829	869	999	958	650	958	782	907	909	612	871
40-49	788	868	909	582	844	914	1,006	969	698	974	829	911	930	628	885
50-59	961	881	1,000	675	899	1,090	1,078	1,088	713	1,066	1,006	950	1,033	693	958
60-64	1,080	973	1,050	707	1,004	1,249	1,097	1,183	783	1,137	1,145	1,030	1,112	732	1,061
65-69	1,201	1,072	1,209	718	1,127	1,358	1,230	1,272	772	1,263	1,264	1,152	1,240	746	1,189
70-79	1,318	1,177	1,303	854	1,262	1,478	1,371	1,357	795	1,402	1,381	1,290	1,332	825	1,328
80+	1,452	1,460	1,530	975	1,438	1,605	1,592	1,521	836	1,564	1,517	1,541	1,524	896	1,498
All	1,201	960	1,056	750	1,063	1,380	1,200	1,195	768	1,257	1,271	1,062	1,119	759	1,142
GLOMERULONEPHRITIS															
0-19	736	944	826	665	813	849	1,190	923	736	955	793	1,052	910	700	883
20-29	637	714	729	585	668	817	994	819	651	884	707	827	770	614	755
30-39	619	774	728	527	676	774	911	812	584	820	675	830	770	552	732
40-49	712	884	752	533	770	772	921	823	595	810	735	898	776	563	785
50-59	793	888	848	632	817	930	971	932	654	920	846	921	880	643	858
60-64	942	995	907	705	947	1,003	1,064	966	724	1,012	965	1,026	928	714	973
65-69	1,049	1,077	991	713	1,039	1,122	1,094	986	716	1,092	1,078	1,086	988	714	1,062
70-79	1,134	1,080	1,116	762	1,111	1,281	1,186	1,045	755	1,222	1,187	1,134	1,078	759	1,155
80+	1,362	1,426	1,271	897	1,346	1,449	1,410	1,258	846	1,405	1,398	1,417	1,262	871	1,372
All	871	872	824	616	857	991	999	902	656	968	916	924	859	635	901
OTHER															
0-19	765	1,024	1,018	786	834	877	1,265	1,193	944	983	812	1,126	1,119	845	897
20-29	670	905	886	680	746	934	1,204	1,056	819	1,026	783	1,049	973	753	873
30-39	719	978	883	636	813	880	1,108	1,005	769	965	792	1,041	940	708	884
40-49	749	948	904	654	829	885	1,098	987	749	963	809	1,013	939	706	888
50-59	840	948	961	761	876	948	1,085	1,100	778	987	893	1,012	1,028	770	930
60-64	981	1,074	1,100	736	1,002	1,082	1,154	1,127	832	1,098	1,030	1,116	1,113	785	1,050
65-69	1,057	1,097	1,156	795	1,058	1,200	1,237	1,249	834	1,198	1,124	1,170	1,205	814	1,126
70-79	1,204	1,168	1,255	832	1,187	1,317	1,377	1,272	921	1,315	1,254	1,273	1,265	879	1,246
80+	1,373	1,448	1,418	980	1,373	1,513	1,564	1,504	969	1,505	1,430	1,509	1,452	975	1,430
All	956	1,012	1,010	747	967	1,085	1,179	1,121	820	1,104	1,015	1,092	1,064	786	1,031
ALL															
0-19	761	990	986	737	830	872	1,243	1,063	832	981	810	1,098	1,039	779	897
20-29	709	816	798	625	753	947	1,135	1,006	742	1,018	809	948	908	677	864
30-39	838	925	915	617	869	958	1,091	1,020	727	1,007	886	992	962	668	924
40-49	899	949	1,020	642	916	1,021	1,127	1,151	727	1,058	947	1,015	1,071	682	971
50-59	1,025	989	1,151	798	1,004	1,191	1,222	1,285	838	1,193	1,095	1,090	1,217	818	1,086
60-64	1,170	1,089	1,245	836	1,128	1,343	1,258	1,301	920	1,288	1,248	1,178	1,274	877	1,206
65-69	1,238	1,149	1,282	866	1,194	1,399	1,311	1,292	908	1,341	1,315	1,242	1,289	888	1,270
70-79	1,329	1,216	1,309	901	1,285	1,485	1,428	1,342	916	1,436	1,399	1,345	1,330	909	1,362
80+	1,464	1,473	1,471	987	1,447	1,625	1,623	1,487	926	1,589	1,535	1,567	1,481	954	1,517
All	1,132	1,035	1,142	794	1,084	1,307	1,280	1,260	852	1,275	1,208	1,154	1,204	823	1,172

On our website: counts of first admissions and years at risk used to compute first admission rates (Table E.1.1).

Table E.2
First Admissions per 1,000 Patient Years: All Dialysis Patients

period prevalent patients, 1999

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	2,198	2,066	1,988	1,911	2,174	2,682	2,540	2,246	2,158	2,544	2,225	2,481	2,117	2,035	2,385
20-29	1,673	1,662	1,490	1,342	1,662	2,010	1,972	1,622	1,505	1,965	1,828	1,847	1,613	1,432	1,822
30-39	1,668	1,567	1,328	1,170	1,619	1,770	1,752	1,512	1,344	1,740	1,704	1,654	1,406	1,256	1,667
40-49	1,529	1,367	1,304	1,058	1,448	1,716	1,563	1,464	1,210	1,623	1,600	1,462	1,368	1,119	1,522
50-59	1,409	1,255	1,341	1,111	1,336	1,652	1,477	1,402	1,203	1,541	1,512	1,372	1,373	1,154	1,434
60-64	1,467	1,259	1,412	1,091	1,373	1,634	1,418	1,409	1,085	1,503	1,549	1,354	1,410	1,088	1,444
65-69	1,491	1,270	1,365	1,038	1,391	1,577	1,398	1,330	1,052	1,473	1,538	1,352	1,342	1,045	1,439
70-79	1,534	1,314	1,357	1,024	1,449	1,628	1,508	1,375	1,020	1,546	1,584	1,445	1,369	1,022	1,506
80+	1,712	1,531	1,536	1,019	1,620	1,842	1,720	1,521	1,035	1,744	1,782	1,661	1,525	1,028	1,693
All	1,512	1,310	1,355	1,059	1,422	1,651	1,491	1,396	1,083	1,551	1,580	1,418	1,378	1,072	1,491
HYPERTENSION															
0-19	1,164	1,082	1,160	982	1,106	1,391	1,352	1,310	1,108	1,362	1,249	1,196	1,235	1,045	1,211
20-29	914	816	933	748	833	1,042	1,037	1,038	821	1,032	971	881	992	774	900
30-39	953	936	959	761	936	1,066	1,063	1,009	794	1,054	991	977	975	776	975
40-49	938	911	991	707	913	1,086	1,059	1,007	825	1,057	984	957	997	753	958
50-59	1,119	928	1,063	799	975	1,233	1,122	1,116	834	1,139	1,160	998	1,084	816	1,034
60-64	1,214	999	1,084	811	1,068	1,365	1,131	1,217	859	1,193	1,274	1,059	1,146	829	1,123
65-69	1,266	1,081	1,243	775	1,164	1,413	1,244	1,281	814	1,293	1,326	1,163	1,262	796	1,224
70-79	1,332	1,182	1,311	874	1,274	1,486	1,378	1,354	808	1,410	1,394	1,297	1,334	841	1,338
80+	1,453	1,471	1,559	999	1,442	1,605	1,597	1,535	842	1,566	1,517	1,549	1,543	910	1,501
All	1,282	1,003	1,122	838	1,125	1,445	1,238	1,225	823	1,307	1,347	1,104	1,171	830	1,201
GLOMERULONEPHRITIS															
0-19	1,179	1,177	1,035	998	1,167	1,365	1,408	1,128	1,079	1,356	1,259	1,289	1,113	1,037	1,256
20-29	915	796	806	778	847	1,058	1,076	874	822	1,048	972	912	838	799	930
30-39	845	857	812	684	840	1,014	1,004	884	769	992	907	918	849	716	900
40-49	932	951	833	668	924	969	1,007	879	751	965	946	971	846	707	939
50-59	995	954	915	786	968	1,151	1,019	985	784	1,071	1,056	980	940	785	1,009
60-64	1,147	1,050	964	825	1,102	1,186	1,112	1,007	823	1,139	1,163	1,079	981	824	1,118
65-69	1,183	1,132	1,031	795	1,154	1,235	1,114	1,000	768	1,170	1,205	1,122	1,013	781	1,161
70-79	1,164	1,094	1,142	801	1,139	1,312	1,198	1,047	784	1,248	1,218	1,148	1,090	792	1,182
80+	1,373	1,449	1,303	939	1,360	1,456	1,429	1,282	875	1,415	1,408	1,438	1,288	907	1,384
All	1,064	947	899	754	1,006	1,179	1,071	961	787	1,110	1,108	999	927	769	1,048
OTHER															
0-19	1,346	1,343	1,339	1,212	1,343	1,414	1,551	1,537	1,374	1,462	1,377	1,442	1,426	1,311	1,399
20-29	928	1,021	1,050	913	964	1,279	1,322	1,192	1,027	1,286	1,075	1,170	1,129	979	1,111
30-39	948	1,086	1,037	824	1,004	1,150	1,221	1,130	983	1,177	1,037	1,150	1,082	903	1,083
40-49	970	1,015	1,013	806	987	1,134	1,185	1,115	891	1,146	1,043	1,087	1,050	851	1,056
50-59	1,063	1,008	1,066	878	1,036	1,184	1,156	1,217	913	1,164	1,123	1,077	1,132	897	1,098
60-64	1,149	1,139	1,205	845	1,138	1,260	1,205	1,226	926	1,230	1,203	1,175	1,215	887	1,185
65-69	1,157	1,121	1,221	847	1,137	1,306	1,255	1,300	895	1,277	1,228	1,192	1,266	870	1,206
70-79	1,231	1,170	1,292	846	1,209	1,336	1,389	1,299	935	1,333	1,278	1,279	1,296	892	1,266
80+	1,377	1,450	1,465	986	1,378	1,516	1,569	1,558	968	1,509	1,434	1,513	1,502	977	1,434
All	1,136	1,082	1,127	859	1,110	1,276	1,255	1,232	937	1,256	1,200	1,164	1,176	900	1,178
ALL															
0-19	1,301	1,264	1,285	1,076	1,280	1,401	1,502	1,296	1,225	1,433	1,346	1,379	1,292	1,156	1,352
20-29	984	897	891	831	933	1,252	1,232	1,087	935	1,224	1,096	1,037	999	882	1,057
30-39	1,110	1,015	1,029	795	1,051	1,247	1,186	1,108	936	1,201	1,163	1,084	1,065	857	1,111
40-49	1,142	1,006	1,110	792	1,055	1,277	1,200	1,248	886	1,219	1,195	1,078	1,162	835	1,118
50-59	1,217	1,044	1,240	935	1,125	1,395	1,274	1,342	973	1,317	1,293	1,146	1,290	954	1,209
60-64	1,317	1,127	1,314	948	1,223	1,472	1,291	1,358	997	1,364	1,389	1,215	1,337	973	1,294
65-69	1,327	1,168	1,308	916	1,255	1,462	1,324	1,302	941	1,380	1,393	1,258	1,304	929	1,321
70-79	1,349	1,222	1,321	916	1,302	1,498	1,434	1,342	922	1,446	1,417	1,352	1,334	920	1,375
80+	1,467	1,482	1,499	996	1,451	1,625	1,629	1,501	923	1,591	1,537	1,573	1,500	957	1,520
All	1,287	1,090	1,220	898	1,195	1,450	1,326	1,310	937	1,372	1,359	1,207	1,268	918	1,278

On our website: counts of first admissions and years at risk used to compute first admission rates (Table E.2.1).

Table E.3
First Admissions per 1,000 Patient Years: All Hemodialysis Patients
period prevalent patients, 1999

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	2,113	1,944	1,914	1,824	2,082	2,650	2,432	2,204	2,112	2,466	2,142	2,226	2,059	1,968	2,169
20-29	1,640	1,606	1,474	1,317	1,620	2,096	1,920	1,618	1,503	1,971	1,829	1,793	1,608	1,414	1,798
30-39	1,648	1,566	1,341	1,167	1,603	1,812	1,745	1,544	1,335	1,756	1,701	1,650	1,423	1,251	1,662
40-49	1,545	1,358	1,287	1,071	1,447	1,727	1,538	1,442	1,228	1,610	1,613	1,445	1,347	1,133	1,515
50-59	1,386	1,236	1,317	1,089	1,313	1,627	1,458	1,394	1,197	1,519	1,489	1,352	1,357	1,140	1,411
60-64	1,451	1,250	1,419	1,084	1,358	1,621	1,404	1,397	1,079	1,487	1,535	1,342	1,407	1,081	1,429
65-69	1,483	1,255	1,389	1,057	1,380	1,566	1,389	1,327	1,063	1,462	1,529	1,341	1,347	1,061	1,429
70-79	1,527	1,315	1,380	1,023	1,442	1,624	1,498	1,386	1,007	1,539	1,579	1,439	1,384	1,013	1,500
80+	1,705	1,521	1,543	1,025	1,611	1,844	1,724	1,508	1,041	1,746	1,779	1,661	1,517	1,033	1,690
All	1,502	1,298	1,353	1,059	1,409	1,642	1,478	1,391	1,078	1,539	1,571	1,406	1,375	1,069	1,479
HYPERTENSION															
0-19	1,126	1,020	1,122	939	1,043	1,434	1,304	1,314	1,104	1,326	1,225	1,133	1,218	1,022	1,151
20-29	902	780	925	729	801	1,107	1,030	1,060	845	1,047	982	850	984	751	875
30-39	951	924	965	739	925	1,095	1,052	1,053	818	1,053	997	964	980	770	966
40-49	935	899	994	701	903	1,115	1,067	1,048	837	1,069	989	949	1,013	752	952
50-59	1,115	914	1,047	797	960	1,227	1,108	1,128	842	1,128	1,155	982	1,081	818	1,020
60-64	1,209	998	1,081	806	1,062	1,394	1,118	1,234	884	1,190	1,280	1,052	1,150	834	1,117
65-69	1,269	1,068	1,232	764	1,153	1,424	1,241	1,287	827	1,292	1,332	1,155	1,261	797	1,217
70-79	1,333	1,177	1,312	884	1,272	1,499	1,375	1,365	806	1,414	1,400	1,293	1,342	845	1,339
80+	1,465	1,468	1,560	1,001	1,451	1,616	1,594	1,543	846	1,572	1,529	1,546	1,548	912	1,509
All	1,289	994	1,118	839	1,120	1,467	1,239	1,261	828	1,315	1,359	1,099	1,184	833	1,201
GLOMERULONEPHRITIS															
0-19	1,127	1,093	973	978	1,101	1,352	1,293	1,086	1,090	1,280	1,203	1,178	1,066	1,038	1,175
20-29	887	770	781	785	820	1,058	1,014	883	856	1,019	950	865	824	817	896
30-39	824	842	797	704	826	1,032	1,004	888	780	1,001	894	904	831	732	889
40-49	920	951	824	684	921	1,006	1,018	873	792	993	950	972	838	729	945
50-59	980	935	892	795	951	1,170	1,004	974	808	1,075	1,050	961	920	801	999
60-64	1,146	1,049	967	841	1,100	1,182	1,133	1,007	849	1,146	1,160	1,086	984	845	1,119
65-69	1,186	1,115	1,020	798	1,152	1,239	1,126	993	782	1,171	1,207	1,121	1,005	790	1,160
70-79	1,152	1,105	1,127	831	1,131	1,324	1,195	1,048	815	1,256	1,215	1,152	1,085	823	1,181
80+	1,385	1,467	1,297	968	1,371	1,484	1,434	1,273	910	1,438	1,426	1,449	1,281	940	1,400
All	1,057	938	886	773	998	1,207	1,066	972	816	1,125	1,113	988	921	793	1,047
OTHER															
0-19	1,279	1,239	1,299	1,184	1,264	1,453	1,480	1,533	1,379	1,463	1,356	1,357	1,383	1,319	1,356
20-29	924	1,018	1,046	907	961	1,284	1,283	1,232	1,080	1,275	1,063	1,149	1,140	996	1,098
30-39	936	1,075	1,066	828	997	1,177	1,192	1,182	1,018	1,180	1,036	1,127	1,117	911	1,075
40-49	960	1,007	1,013	818	980	1,166	1,178	1,134	944	1,162	1,046	1,075	1,051	883	1,055
50-59	1,067	989	1,067	868	1,028	1,195	1,169	1,213	927	1,175	1,129	1,070	1,133	899	1,098
60-64	1,158	1,129	1,220	872	1,141	1,276	1,204	1,249	976	1,240	1,214	1,169	1,234	924	1,190
65-69	1,172	1,107	1,235	859	1,143	1,328	1,252	1,318	935	1,290	1,245	1,183	1,278	895	1,215
70-79	1,228	1,167	1,303	873	1,207	1,349	1,384	1,332	961	1,343	1,282	1,275	1,319	919	1,270
80+	1,372	1,447	1,489	1,024	1,374	1,517	1,571	1,571	996	1,511	1,431	1,512	1,524	1,010	1,433
All	1,137	1,072	1,139	873	1,108	1,298	1,250	1,261	970	1,269	1,209	1,155	1,193	922	1,181
ALL															
0-19	1,242	1,162	1,241	1,052	1,203	1,433	1,407	1,244	1,241	1,405	1,321	1,274	1,243	1,167	1,293
20-29	971	869	880	836	912	1,273	1,194	1,139	985	1,216	1,087	1,000	1,009	903	1,033
30-39	1,085	1,001	1,016	805	1,031	1,269	1,177	1,168	960	1,206	1,151	1,068	1,072	869	1,096
40-49	1,137	997	1,107	807	1,047	1,312	1,204	1,262	934	1,236	1,202	1,071	1,162	861	1,116
50-59	1,208	1,028	1,224	928	1,109	1,398	1,266	1,336	991	1,314	1,288	1,131	1,279	958	1,197
60-64	1,311	1,121	1,325	954	1,215	1,478	1,284	1,351	1,015	1,361	1,388	1,207	1,338	985	1,288
65-69	1,330	1,154	1,320	924	1,248	1,469	1,319	1,300	956	1,379	1,398	1,249	1,307	941	1,318
70-79	1,346	1,221	1,334	930	1,299	1,506	1,428	1,356	924	1,448	1,420	1,348	1,348	926	1,376
80+	1,472	1,478	1,509	1,008	1,455	1,635	1,629	1,498	934	1,598	1,544	1,572	1,502	968	1,525
All	1,286	1,081	1,220	909	1,189	1,467	1,325	1,323	952	1,380	1,366	1,200	1,274	931	1,278

On our website: counts of first admissions and years at risk used to compute first admission rates (Table E.3.1).

Table E.4
First Admissions per 1,000 Patient Years: All CAPD/CCPD Patients
period prevalent patients, 1999

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	2,250	2,354	2,118	2,115	2,209	2,535	2,716	2,275	2,355	2,715	2,392	2,716	2,197	2,235	2,714
20-29	1,752	1,809	1,627	1,550	1,771	1,967	2,081	1,742	1,720	1,992	1,894	1,973	1,742	1,719	1,915
30-39	1,586	1,617	1,454	1,321	1,583	1,774	1,853	1,550	1,461	1,778	1,667	1,728	1,500	1,384	1,669
40-49	1,467	1,477	1,327	1,151	1,459	1,636	1,686	1,410	1,268	1,630	1,535	1,582	1,373	1,207	1,532
50-59	1,560	1,551	1,392	1,152	1,538	1,733	1,764	1,475	1,265	1,711	1,633	1,677	1,443	1,209	1,621
60-64	1,567	1,537	1,380	1,089	1,542	1,735	1,743	1,456	1,192	1,704	1,643	1,651	1,422	1,151	1,621
65-69	1,547	1,498	1,344	1,012	1,503	1,706	1,692	1,413	1,103	1,665	1,620	1,619	1,377	1,055	1,584
70-79	1,584	1,515	1,358	976	1,548	1,741	1,705	1,423	1,060	1,684	1,652	1,625	1,397	1,024	1,612
80+	1,611	1,521	1,362	934	1,575	1,764	1,706	1,422	1,011	1,693	1,695	1,686	1,392	989	1,645
All	1,553	1,534	1,377	1,071	1,529	1,725	1,743	1,456	1,161	1,696	1,629	1,654	1,422	1,119	1,609
HYPERTENSION															
0-19	1,200	1,337	1,269	1,101	1,251	1,270	1,449	1,280	1,151	1,359	1,231	1,400	1,274	1,126	1,305
20-29	998	1,097	1,041	861	1,050	1,052	1,185	1,046	898	1,087	1,031	1,136	1,046	888	1,070
30-39	964	1,047	992	784	1,017	1,013	1,126	994	814	1,071	986	1,080	994	804	1,041
40-49	952	1,021	967	729	988	997	1,094	965	754	1,050	970	1,054	966	741	1,015
50-59	1,081	1,144	1,083	779	1,103	1,128	1,222	1,077	803	1,164	1,098	1,180	1,082	793	1,129
60-64	1,159	1,211	1,146	786	1,156	1,205	1,289	1,136	808	1,220	1,180	1,259	1,140	798	1,190
65-69	1,221	1,260	1,192	780	1,217	1,265	1,336	1,177	798	1,261	1,239	1,305	1,188	792	1,237
70-79	1,335	1,359	1,285	803	1,307	1,378	1,437	1,265	819	1,365	1,353	1,402	1,281	808	1,332
80+	1,450	1,457	1,377	821	1,420	1,491	1,535	1,350	834	1,450	1,466	1,503	1,362	827	1,432
All	1,230	1,122	1,120	788	1,172	1,269	1,222	1,048	810	1,221	1,246	1,171	1,079	799	1,194
GLOMERULONEPHRITIS															
0-19	1,268	1,341	1,253	1,021	1,274	1,291	1,398	1,216	1,027	1,321	1,280	1,381	1,216	1,024	1,301
20-29	1,033	1,078	1,006	782	1,024	1,047	1,120	973	784	1,052	1,040	1,101	985	783	1,039
30-39	977	1,007	939	697	964	988	1,042	905	696	992	983	1,030	905	697	980
40-49	945	961	897	635	923	952	992	861	632	928	949	978	882	633	925
50-59	1,051	1,055	983	664	1,028	1,055	1,085	941	659	1,024	1,053	1,071	967	661	1,026
60-64	1,103	1,094	1,019	657	1,081	1,104	1,120	971	649	1,089	1,103	1,112	1,014	652	1,085
65-69	1,138	1,114	1,037	638	1,106	1,135	1,137	985	628	1,128	1,137	1,131	986	636	1,117
70-79	1,219	1,178	1,096	643	1,193	1,210	1,198	1,037	631	1,176	1,216	1,187	1,055	637	1,186
80+	1,296	1,236	1,149	643	1,291	1,282	1,253	1,084	629	1,255	1,290	1,241	1,106	629	1,275
All	1,086	1,039	972	679	1,048	1,070	1,077	933	670	1,041	1,079	1,061	946	674	1,045
OTHER															
0-19	1,326	1,547	1,402	1,210	1,392	1,416	1,692	1,427	1,276	1,485	1,371	1,611	1,427	1,239	1,437
20-29	1,071	1,233	1,117	920	1,125	1,139	1,344	1,133	967	1,195	1,108	1,293	1,130	957	1,164
30-39	1,005	1,143	1,035	813	1,040	1,065	1,241	1,046	851	1,124	1,038	1,207	1,041	838	1,090
40-49	964	1,083	980	734	987	1,019	1,171	986	766	1,057	995	1,137	983	753	1,028
50-59	1,064	1,179	1,066	762	1,083	1,119	1,271	1,070	793	1,151	1,095	1,238	1,067	784	1,123
60-64	1,108	1,212	1,095	747	1,100	1,162	1,302	1,095	775	1,174	1,138	1,275	1,095	760	1,143
65-69	1,134	1,224	1,106	720	1,129	1,185	1,311	1,102	744	1,178	1,160	1,268	1,102	734	1,155
70-79	1,204	1,284	1,159	720	1,185	1,254	1,369	1,151	741	1,238	1,226	1,330	1,151	729	1,209
80+	1,270	1,337	1,206	715	1,243	1,318	1,421	1,193	733	1,310	1,292	1,401	1,205	721	1,275
All	1,106	1,190	1,052	760	1,109	1,148	1,267	1,083	809	1,163	1,128	1,237	1,071	789	1,139
ALL															
0-19	1,307	1,495	1,511	1,123	1,357	1,377	1,607	1,364	1,131	1,444	1,342	1,556	1,365	1,127	1,402
20-29	1,092	1,175	1,025	812	1,108	1,179	1,275	1,054	891	1,189	1,141	1,229	1,046	861	1,153
30-39	1,192	1,140	1,248	800	1,160	1,228	1,211	1,055	835	1,198	1,210	1,180	1,105	820	1,180
40-49	1,146	1,084	1,060	746	1,102	1,172	1,170	1,088	748	1,141	1,158	1,129	1,076	748	1,121
50-59	1,262	1,247	1,240	876	1,243	1,312	1,392	1,389	873	1,321	1,286	1,326	1,317	874	1,282
60-64	1,330	1,351	1,256	853	1,315	1,405	1,435	1,379	924	1,393	1,365	1,402	1,316	892	1,355
65-69	1,311	1,354	1,320	862	1,297	1,389	1,478	1,330	923	1,388	1,347	1,430	1,325	892	1,342
70-79	1,360	1,389	1,315	803	1,336	1,440	1,523	1,313	870	1,423	1,393	1,463	1,314	833	1,374
80+	1,408	1,395	1,259	812	1,382	1,469	1,558	1,259	858	1,442	1,435	1,503	1,259	837	1,409
All	1,278	1,216	1,215	817	1,242	1,329	1,332	1,219	851	1,303	1,301	1,280	1,218	835	1,272

On our website: counts of first admissions and years at risk used to compute first admission rates (Table E.4.1).

Table E.5
First Admissions per 1,000 Patient Years: All Transplant Patients
period prevalent patients, 1999; first three years after transplant

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	955	1,251	1,014	818	958	1,341	1,775	1,633	1,252	1,342	1,295	1,513	1,324	1,035	1,295
20-29	674	863	703	535	718	851	1,135	1,084	782	929	765	1,017	1,082	659	830
30-39	613	756	607	437	628	746	939	909	614	775	666	843	700	520	688
40-49	558	694	586	388	574	676	861	808	529	702	601	755	698	437	621
50-59	569	667	576	367	583	644	804	783	470	698	594	728	670	397	625
60-64	600	696	605	362	612	689	787	767	440	706	629	734	693	398	646
65-69	593	712	640	358	610	684	774	772	414	697	625	736	664	377	641
70-79	663	746	674	358	660	672	774	785	396	705	665	758	675	363	672
80+	429	474	430	215	429	416	462	478	227	396	429	468	454	221	429
All	586	703	593	375	601	701	854	793	486	732	628	768	684	415	651
HYPERTENSION															
0-19	490	662	672	369	584	669	907	1,042	542	690	585	715	857	541	631
20-29	377	504	512	264	443	496	653	760	372	587	417	552	666	281	490
30-39	363	464	490	236	411	451	579	690	318	515	388	497	562	258	441
40-49	379	512	507	233	450	447	575	686	301	508	401	531	538	260	469
50-59	416	504	558	242	456	480	585	721	292	512	437	528	593	267	474
60-64	473	601	645	262	499	523	621	788	307	565	489	609	788	267	521
65-69	555	686	733	281	571	572	690	862	313	599	561	688	733	292	581
70-79	662	771	858	313	661	657	744	960	329	680	661	758	909	316	667
80+	464	527	600	204	505	435	497	642	207	436	462	527	621	206	504
All	443	517	524	250	470	498	602	720	307	538	461	544	575	270	492
GLOMERULONEPHRITIS															
0-19	419	624	551	353	486	558	857	847	515	622	495	710	823	438	555
20-29	304	450	416	249	343	432	611	617	352	481	352	512	485	288	395
30-39	290	425	392	219	322	365	521	553	291	399	316	461	460	259	350
40-49	306	444	401	213	328	363	509	549	272	387	326	470	480	244	351
50-59	346	466	438	215	361	382	537	569	268	397	359	491	507	244	375
60-64	397	527	500	237	407	420	568	616	277	433	405	541	500	250	416
65-69	445	577	563	250	451	456	609	665	280	475	449	590	563	254	459
70-79	519	657	650	272	525	501	652	733	291	501	514	655	650	282	517
80+	358	453	451	177	358	337	427	485	181	358	358	440	468	179	358
All	335	462	431	228	357	401	561	595	291	428	359	499	505	259	384
OTHER															
0-19	448	635	538	448	487	592	874	848	673	650	506	721	774	504	550
20-29	325	467	403	316	351	457	637	615	457	488	384	539	491	379	412
30-39	322	429	382	280	342	429	570	556	383	460	374	505	450	344	401
40-49	336	444	399	274	352	397	552	544	364	430	362	499	498	328	388
50-59	364	486	431	288	383	407	561	568	351	433	384	522	526	327	407
60-64	427	549	495	303	446	450	594	620	365	468	438	567	583	335	457
65-69	479	614	562	325	491	492	649	676	368	505	485	629	566	348	497
70-79	557	697	649	355	563	572	694	744	387	582	562	695	697	376	570
80+	391	477	451	232	396	375	457	494	241	392	391	477	473	237	396
All	373	493	429	310	392	442	599	608	387	470	404	544	534	352	428
ALL															
0-19	444	633	541	422	489	586	870	848	581	643	505	717	790	483	554
20-29	351	495	421	274	387	503	696	667	399	550	415	575	526	322	454
30-39	407	480	457	256	421	511	618	635	348	530	449	536	524	304	465
40-49	403	512	499	251	425	476	591	654	320	497	431	542	572	285	453
50-59	428	537	546	281	453	463	645	704	323	506	442	578	622	301	474
60-64	479	614	576	294	501	507	673	731	382	546	490	638	660	326	519
65-69	515	664	619	299	532	543	696	765	356	567	525	677	636	319	545
70-79	596	736	664	323	603	583	731	806	335	608	592	734	664	327	605
80+	398	524	483	207	431	433	461	524	214	430	399	524	504	211	431
All	428	532	518	276	448	498	645	693	345	528	456	577	599	308	480

On our website: counts of first admissions and years at risk used to compute first admission rates (Table E.5.1).

Table E.6
First Admission Standardized Hospitalization Ratios
by state, all period prevalent dialysis patients

	1997-1999	1997	1998	1999
Alabama	1.07	1.06	1.07	1.08
Alaska	0.86	0.91	0.85	0.82
Arizona	0.91	0.89	0.91	0.94
Arkansas	1.12	1.13	1.12	1.11
California	0.93	0.95	0.93	0.92
Colorado	0.88	0.89	0.86	0.89
Connecticut	0.96	1.04	0.93	0.92
Delaware	0.95	0.95	1.00	0.92
District of Columbia	1.10	1.17	1.06	1.08
Florida	1.02	1.02	1.01	1.03
Georgia	1.04	1.07	1.03	1.02
Hawaii	1.08	1.07	1.11	1.06
Idaho	0.84	0.82	0.88	0.83
Illinois	1.05	1.07	1.05	1.04
Indiana	1.00	1.03	1.01	0.97
Iowa	0.97	0.96	0.96	0.99
Kansas	1.05	1.03	1.05	1.07
Kentucky	1.05	1.04	1.05	1.06
Louisiana	1.17	1.17	1.19	1.17
Maine	1.01	1.02	1.02	1.00
Maryland	1.04	1.01	1.02	1.08
Massachusetts	1.04	1.02	1.03	1.07
Michigan	0.98	0.99	0.97	0.98
Minnesota	0.94	0.96	0.97	0.89
Mississippi	0.97	1.00	0.98	0.93
Missouri	0.98	0.94	0.99	1.02
Montana	0.80	0.77	0.79	0.83
Nebraska	0.89	0.85	0.93	0.89
Nevada	0.97	0.95	0.98	0.98
New Hampshire	1.03	1.01	1.07	1.00
New Jersey	1.09	1.11	1.09	1.08
New Mexico	0.86	0.87	0.89	0.81
New York	0.94	0.96	0.94	0.93
North Carolina	1.10	1.08	1.10	1.10
North Dakota	0.81	0.76	0.84	0.84
Ohio	1.05	1.06	1.02	1.06
Oklahoma	1.03	0.98	1.03	1.07
Oregon	0.88	0.90	0.88	0.88
Pennsylvania	1.12	1.15	1.09	1.12
Rhode Island	1.06	1.08	1.05	1.05
South Carolina	1.00	1.01	0.99	1.02
South Dakota	1.05	1.07	1.05	1.02
Tennessee	1.00	1.00	1.01	0.99
Texas	0.97	0.99	0.96	0.96
Utah	0.80	0.79	0.81	0.80
Vermont	0.86	0.91	0.82	0.86
Virginia	0.97	0.99	0.97	0.96
Washington	0.87	0.88	0.83	0.88
West Virginia	1.20	1.23	1.19	1.20
Wisconsin	0.93	0.96	0.95	0.89
Wyoming	0.81	0.79	0.88	0.76
American Samoa	0.95	0.61	1.31	1.02
Guam	0.90	0.99	0.86	0.87
Northern Marianas	0.93	0.38	1.69	0.87
Puerto Rico	1.02	0.98	1.06	1.02
Virgin Islands	0.82	0.78	0.74	0.93
All	1.00	1.01	1.00	1.00

Table E.7

Total Admissions per 1,000 Patient Years: All ESRD Patients, 1999*period prevalent patients*

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*			*	*	*			*	*	*			*
20-29	2,372	3,038			2,581	2,538	3,369	2,317		2,885	2,454	3,233	2,488	2,351	2,744
30-39	2,168	2,378	1,812	760	2,188	2,253	2,727	2,989	2,029	2,416	2,200	2,551	2,381	1,439	2,283
40-49	2,002	2,108	1,943	1,324	2,017	2,248	2,427	2,096	1,692	2,299	2,098	2,265	2,011	1,487	2,138
50-59	1,950	1,931	1,953	1,490	1,928	2,328	2,233	1,977	1,792	2,251	2,114	2,095	1,966	1,625	2,084
60-64	2,039	1,899	2,020	1,388	1,968	2,300	2,104	2,025	1,498	2,172	2,168	2,023	2,023	1,450	2,079
65-69	2,067	1,871	2,017	1,517	1,979	2,295	2,152	2,069	1,725	2,208	2,193	2,055	2,051	1,629	2,115
70-79	2,186	1,996	1,965	1,533	2,105	2,291	2,225	1,929	1,587	2,227	2,243	2,154	1,942	1,566	2,178
80+	2,276	2,209	2,533	1,661	2,225	2,548	2,538	2,087	1,841	2,501	2,425	2,442	2,207	1,759	2,392
All	2,081	1,999	1,978	1,463	2,031	2,312	2,258	2,041	1,684	2,259	2,193	2,156	2,013	1,582	2,153
HYPERTENSION															
0-19	1,779	675	.	.	1,108	2,390	1,299	.	*	1,673	2,056	938	.	*	1,361
20-29	1,341	1,187	*	1,017	1,213	1,273	1,492	1,552	978	1,413	1,312	1,283	1,293	1,005	1,283
30-39	1,187	1,525	1,507	1,226	1,444	1,389	1,746	2,103	853	1,644	1,256	1,598	1,693	1,086	1,511
40-49	1,270	1,434	1,247	865	1,385	1,451	1,678	1,525	1,399	1,618	1,330	1,512	1,344	1,100	1,461
50-59	1,549	1,415	1,827	1,127	1,450	1,845	1,723	1,753	1,049	1,732	1,655	1,529	1,798	1,089	1,554
60-64	1,642	1,502	1,563	840	1,534	2,030	1,643	2,251	1,536	1,771	1,797	1,568	1,969	1,101	1,639
65-69	1,675	1,602	1,845	987	1,624	2,016	1,900	2,489	1,239	1,928	1,816	1,757	2,186	1,122	1,767
70-79	1,901	1,782	1,561	1,330	1,847	2,071	2,146	2,101	1,184	2,075	1,971	2,001	1,875	1,261	1,957
80+	1,948	2,090	2,952	1,639	1,969	2,209	2,357	2,129	1,145	2,217	2,061	2,257	2,402	1,370	2,090
All	1,746	1,527	1,597	1,185	1,618	2,008	1,895	1,987	1,192	1,919	1,852	1,689	1,784	1,188	1,746
GLOMERULONEPHRITIS															
0-19	1,537	1,596	*	973	1,530	1,407	1,948	*	942	1,573	1,473	1,767	*	958	1,552
20-29	1,049	1,169	1,159	951	1,096	1,437	1,580	935	835	1,457	1,210	1,350	1,050	901	1,251
30-39	999	1,317	1,333	639	1,113	1,229	1,542	1,121	950	1,347	1,085	1,412	1,225	778	1,207
40-49	1,159	1,487	1,207	727	1,274	1,175	1,537	1,292	749	1,281	1,165	1,505	1,237	738	1,276
50-59	1,226	1,368	1,214	922	1,259	1,362	1,441	1,991	892	1,363	1,280	1,397	1,541	907	1,301
60-64	1,509	1,414	1,086	1,472	1,474	1,450	1,536	1,743	1,493	1,486	1,487	1,470	1,355	1,481	1,479
65-69	1,608	1,593	1,546	1,081	1,584	1,528	1,864	910	1,152	1,589	1,576	1,731	1,197	1,115	1,586
70-79	1,602	1,478	1,985	1,108	1,570	1,881	1,670	1,108	1,046	1,779	1,707	1,579	1,571	1,076	1,655
80+	1,737	2,136	*	972	1,745	2,042	2,191	1,073	976	1,997	1,864	2,166	1,089	974	1,855
All	1,334	1,401	1,304	890	1,334	1,491	1,590	1,246	925	1,484	1,395	1,481	1,277	907	1,395
OTHER															
0-19	1,350	1,854	*	1,473	1,492	1,411	2,014	1,591	1,670	1,590	1,376	1,924	1,566	1,560	1,534
20-29	1,152	1,457	1,256	973	1,248	1,662	2,170	1,681	1,513	1,844	1,388	1,823	1,484	1,266	1,536
30-39	1,220	1,783	2,122	770	1,439	1,415	1,939	1,479	1,540	1,630	1,312	1,859	1,807	1,223	1,531
40-49	1,222	1,617	1,294	1,143	1,388	1,400	1,867	1,200	1,115	1,578	1,303	1,730	1,255	1,127	1,474
50-59	1,311	1,480	1,383	1,172	1,367	1,528	1,620	2,115	1,347	1,559	1,418	1,547	1,752	1,271	1,461
60-64	1,588	1,759	1,901	1,166	1,632	1,664	1,799	1,497	1,286	1,695	1,626	1,780	1,709	1,228	1,664
65-69	1,587	1,793	2,113	1,118	1,627	1,779	1,905	2,279	1,659	1,814	1,679	1,852	2,200	1,395	1,720
70-79	1,652	1,690	2,005	1,121	1,648	1,830	2,097	1,585	1,476	1,876	1,733	1,904	1,768	1,315	1,756
80+	1,825	2,090	900	1,804	1,857	2,024	2,285	2,565	1,388	2,062	1,910	2,194	1,657	1,602	1,948
All	1,450	1,660	1,627	1,138	1,507	1,644	1,907	1,695	1,396	1,720	1,541	1,781	1,660	1,279	1,609
ALL															
0-19	1,397	1,706	1,434	1,276	1,491	1,426	1,992	1,170	1,302	1,600	1,410	1,837	1,269	1,288	1,540
20-29	1,255	1,368	1,206	962	1,292	1,670	1,973	1,438	1,236	1,778	1,440	1,637	1,335	1,088	1,510
30-39	1,462	1,638	1,693	794	1,523	1,611	1,916	1,828	1,300	1,739	1,523	1,754	1,757	1,042	1,613
40-49	1,495	1,591	1,579	969	1,528	1,654	1,890	1,753	1,125	1,745	1,558	1,707	1,650	1,046	1,614
50-59	1,614	1,585	1,823	1,239	1,595	1,892	1,917	1,974	1,334	1,885	1,735	1,736	1,898	1,286	1,725
60-64	1,800	1,696	1,895	1,218	1,743	2,028	1,908	2,000	1,468	1,954	1,907	1,811	1,952	1,342	1,849
65-69	1,810	1,740	1,966	1,278	1,771	2,070	2,039	2,047	1,544	2,039	1,938	1,916	2,017	1,419	1,913
70-79	1,899	1,830	1,900	1,350	1,863	2,098	2,160	1,879	1,403	2,091	1,991	2,037	1,887	1,379	1,981
80+	1,948	2,123	2,157	1,592	1,968	2,235	2,406	2,034	1,392	2,252	2,078	2,303	2,074	1,485	2,111
All	1,715	1,661	1,780	1,198	1,679	1,961	2,016	1,908	1,357	1,960	1,825	1,840	1,848	1,279	1,812

* Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

On our website: counts of total admissions and years at risk used to compute total admission rates (Table E.7.1).

Table E.8
Total Admissions per 1,000 Patient Years at Risk: All ESRD Patients, 1997-1999
period prevalent patients

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	1,049	*	.	.	911	*	3,848	.	*	3,296	1,406	2,705	.	*	2,125
20-29	2,249	2,998	.	1,233	2,472	2,607	3,336	2,246	3,183	2,883	2,430	3,196	2,339	2,123	2,693
30-39	2,145	2,541	1,633	1,330	2,213	2,257	2,686	2,550	2,416	2,396	2,188	2,613	2,090	1,922	2,290
40-49	1,987	2,081	2,025	1,435	2,004	2,250	2,398	2,082	1,830	2,291	2,089	2,236	2,050	1,618	2,127
50-59	1,984	1,934	1,821	1,465	1,941	2,344	2,211	2,036	1,819	2,253	2,142	2,085	1,931	1,618	2,092
60-64	2,076	1,885	1,931	1,404	1,978	2,327	2,110	1,990	1,516	2,189	2,202	2,022	1,964	1,463	2,094
65-69	2,116	1,904	2,129	1,554	2,026	2,281	2,145	2,030	1,734	2,196	2,206	2,063	2,066	1,653	2,127
70-79	2,166	1,947	2,001	1,554	2,081	2,344	2,264	1,985	1,627	2,274	2,263	2,166	1,990	1,598	2,197
80+	2,340	2,220	2,121	1,496	2,252	2,549	2,484	2,263	1,829	2,483	2,456	2,409	2,229	1,674	2,394
All	2,090	2,001	1,937	1,489	2,038	2,331	2,256	2,048	1,729	2,270	2,207	2,156	2,000	1,616	2,162
HYPERTENSION															
0-19	1,066	1,076	*	.	1,101	1,133	2,279	*	*	1,608	1,101	1,575	*	*	1,343
20-29	1,101	1,274	1,805	791	1,224	1,270	1,453	1,726	654	1,380	1,172	1,331	1,757	748	1,278
30-39	1,180	1,522	1,914	980	1,435	1,244	1,732	1,106	1,011	1,589	1,202	1,591	1,648	992	1,487
40-49	1,316	1,444	1,592	861	1,406	1,454	1,619	1,325	1,170	1,564	1,361	1,500	1,504	1,000	1,457
50-59	1,506	1,409	1,756	1,182	1,435	1,757	1,699	1,490	1,182	1,694	1,597	1,518	1,640	1,182	1,532
60-64	1,752	1,533	1,578	1,065	1,605	1,970	1,684	2,036	1,325	1,768	1,837	1,604	1,824	1,174	1,677
65-69	1,782	1,638	2,361	1,131	1,705	2,101	1,878	2,036	1,304	1,952	1,913	1,764	2,187	1,222	1,821
70-79	1,905	1,755	1,759	1,361	1,846	2,149	2,079	1,967	1,232	2,087	2,004	1,948	1,883	1,300	1,961
80+	1,950	2,167	2,676	1,447	1,980	2,222	2,297	2,165	1,096	2,206	2,069	2,250	2,320	1,258	2,092
All	1,756	1,539	1,812	1,183	1,630	2,027	1,859	1,779	1,189	1,905	1,865	1,680	1,796	1,186	1,747
GLOMERULONEPHRITIS															
0-19	1,378	1,474	1,072	1,074	1,399	1,320	2,000	1,264	788	1,531	1,350	1,707	1,211	941	1,462
20-29	1,089	1,226	1,277	885	1,139	1,377	1,620	1,054	909	1,448	1,208	1,393	1,179	896	1,269
30-39	1,007	1,371	1,138	671	1,132	1,299	1,503	1,267	841	1,355	1,116	1,426	1,206	747	1,221
40-49	1,125	1,494	1,390	846	1,264	1,263	1,528	1,443	764	1,322	1,177	1,506	1,408	804	1,286
50-59	1,235	1,429	1,162	985	1,284	1,488	1,524	1,854	997	1,472	1,334	1,467	1,453	990	1,359
60-64	1,490	1,503	994	1,117	1,471	1,583	1,509	2,122	1,874	1,580	1,526	1,506	1,502	1,428	1,515
65-69	1,585	1,661	1,352	1,139	1,581	1,683	1,715	1,141	1,098	1,653	1,623	1,688	1,237	1,118	1,612
70-79	1,652	1,628	2,040	1,091	1,630	1,835	1,791	1,303	1,086	1,780	1,723	1,712	1,703	1,088	1,692
80+	1,818	2,095	1,209	1,391	1,826	2,051	2,152	1,973	1,102	2,022	1,917	2,127	1,653	1,251	1,913
All	1,338	1,445	1,316	926	1,351	1,540	1,599	1,428	955	1,521	1,417	1,510	1,367	940	1,420
OTHER															
0-19	1,325	1,751	1,178	1,507	1,435	1,466	2,099	2,101	1,111	1,627	1,382	1,896	1,728	1,322	1,513
20-29	1,137	1,534	1,153	1,022	1,260	1,590	2,126	2,154	1,337	1,778	1,349	1,839	1,670	1,189	1,512
30-39	1,217	1,743	1,872	736	1,411	1,457	1,934	1,534	1,151	1,634	1,330	1,839	1,706	982	1,520
40-49	1,211	1,597	1,214	919	1,359	1,374	1,876	1,263	1,078	1,557	1,285	1,722	1,235	1,006	1,449
50-59	1,350	1,513	1,175	1,307	1,403	1,525	1,720	2,005	1,101	1,580	1,437	1,614	1,572	1,191	1,491
60-64	1,485	1,635	1,850	1,015	1,522	1,640	1,843	1,879	1,405	1,705	1,564	1,745	1,865	1,199	1,616
65-69	1,602	1,757	2,037	1,208	1,634	1,813	1,940	2,369	1,293	1,836	1,707	1,856	2,210	1,255	1,738
70-79	1,714	1,754	2,143	1,294	1,714	1,900	2,052	1,666	1,557	1,923	1,799	1,913	1,875	1,436	1,813
80+	1,858	2,075	1,718	1,699	1,886	2,065	2,315	2,391	1,670	2,111	1,946	2,206	2,056	1,685	1,987
All	1,455	1,654	1,551	1,136	1,507	1,655	1,927	1,806	1,265	1,730	1,549	1,790	1,678	1,206	1,614
ALL															
0-19	1,332	1,609	1,222	1,352	1,414	1,415	2,091	1,739	976	1,603	1,367	1,816	1,554	1,171	1,495
20-29	1,237	1,434	1,366	928	1,310	1,636	1,970	1,700	1,144	1,755	1,417	1,670	1,542	1,028	1,509
30-39	1,458	1,659	1,594	817	1,527	1,641	1,897	1,687	1,184	1,734	1,533	1,759	1,639	997	1,613
40-49	1,481	1,589	1,711	982	1,522	1,655	1,864	1,752	1,101	1,729	1,550	1,696	1,728	1,042	1,605
50-59	1,623	1,595	1,690	1,276	1,601	1,895	1,919	1,974	1,338	1,889	1,742	1,744	1,830	1,305	1,731
60-64	1,800	1,686	1,814	1,211	1,735	2,029	1,919	1,992	1,502	1,961	1,908	1,812	1,911	1,350	1,849
65-69	1,851	1,764	2,089	1,348	1,809	2,089	2,022	2,004	1,496	2,039	1,967	1,917	2,037	1,428	1,931
70-79	1,907	1,814	1,977	1,386	1,868	2,147	2,152	1,914	1,452	2,119	2,018	2,025	1,936	1,422	1,998
80+	1,972	2,158	2,053	1,495	1,989	2,246	2,354	2,228	1,413	2,248	2,097	2,284	2,172	1,452	2,120
All	1,714	1,668	1,771	1,209	1,682	1,971	2,004	1,918	1,343	1,960	1,829	1,837	1,849	1,277	1,814

* Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

On our website: counts of total admissions and years at risk used to compute total admission rates (Table E.8.1).

Table E.9
Total Admissions per 1,000 Patient Years: All Dialysis Patients, 1999
period prevalent patients

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*			*	*	*			*	*	*			*
20-29	3,076	3,535	*	*	3,217	3,339	3,922	2,375	*	3,579	3,206	3,765	2,543	2,351	3,414
30-39	2,781	2,594	2,047	876	2,681	2,906	2,960	2,905	2,209	2,906	2,825	2,776	2,460	1,596	2,772
40-49	2,376	2,206	1,971	1,510	2,278	2,598	2,491	2,252	1,777	2,514	2,464	2,349	2,095	1,629	2,382
50-59	2,130	2,000	2,051	1,641	2,061	2,472	2,281	2,018	1,868	2,341	2,283	2,154	2,034	1,747	2,199
60-64	2,157	1,941	2,136	1,565	2,057	2,367	2,125	2,130	1,579	2,219	2,263	2,054	2,133	1,573	2,147
65-69	2,146	1,896	1,995	1,554	2,034	2,327	2,157	2,076	1,730	2,226	2,247	2,068	2,049	1,650	2,149
70-79	2,200	2,002	1,980	1,551	2,118	2,295	2,226	1,929	1,589	2,230	2,251	2,156	1,947	1,574	2,185
80+	2,276	2,209	2,533	1,661	2,225	2,548	2,538	2,087	1,841	2,501	2,425	2,442	2,207	1,759	2,392
All	2,243	2,052	2,045	1,554	2,151	2,411	2,284	2,080	1,716	2,321	2,327	2,195	2,065	1,643	2,244
HYPERTENSION															
0-19	*	893	.	.	1,330	*	1,432	.	.	1,526	*	1,144	.	.	1,414
20-29	1,745	1,255	*	1,368	1,346	1,405	1,597	1,646	1,005	1,526	1,589	1,362	1,362	1,245	1,409
30-39	1,447	1,635	1,441	1,625	1,599	1,614	1,859	2,159	914	1,791	1,506	1,710	1,667	1,340	1,664
40-49	1,455	1,514	1,445	1,064	1,494	1,680	1,766	1,489	1,684	1,743	1,530	1,596	1,461	1,335	1,576
50-59	1,757	1,485	1,841	1,296	1,555	2,075	1,789	1,731	1,266	1,843	1,873	1,599	1,797	1,282	1,663
60-64	1,787	1,542	1,563	1,023	1,616	2,169	1,679	2,289	1,622	1,835	1,944	1,606	1,988	1,273	1,714
65-69	1,757	1,618	1,888	989	1,673	2,094	1,918	2,489	1,284	1,970	1,898	1,776	2,209	1,152	1,815
70-79	1,920	1,788	1,561	1,341	1,862	2,077	2,153	2,101	1,191	2,081	1,986	2,008	1,875	1,269	1,969
80+	1,949	2,099	2,952	1,639	1,971	2,210	2,357	2,129	1,145	2,217	2,062	2,260	2,402	1,370	2,091
All	1,838	1,591	1,667	1,300	1,696	2,080	1,945	2,009	1,265	1,979	1,937	1,750	1,835	1,283	1,819
GLOMERULONEPHRITIS															
0-19	2,052	1,965	*	*	1,956	2,204	1,941	*	*	1,964	2,119	1,953	*	887	1,960
20-29	1,436	1,322	1,231	1,194	1,365	1,670	1,731	873	931	1,642	1,535	1,507	1,053	1,077	1,487
30-39	1,306	1,469	1,462	768	1,355	1,546	1,675	1,199	1,358	1,590	1,398	1,558	1,326	1,009	1,451
40-49	1,465	1,587	1,289	925	1,493	1,444	1,686	1,529	990	1,516	1,457	1,622	1,365	956	1,501
50-59	1,487	1,466	1,289	1,164	1,460	1,637	1,527	2,199	1,105	1,570	1,548	1,490	1,656	1,135	1,505
60-64	1,796	1,495	1,168	1,728	1,688	1,671	1,577	1,743	1,672	1,637	1,747	1,534	1,421	1,703	1,667
65-69	1,772	1,683	1,619	1,238	1,732	1,653	1,894	910	1,131	1,680	1,723	1,792	1,222	1,184	1,709
70-79	1,635	1,505	2,088	1,112	1,601	1,913	1,683	1,108	1,069	1,806	1,740	1,599	1,613	1,090	1,685
80+	1,744	2,136	*	972	1,751	2,042	2,191	1,073	976	1,997	1,868	2,166	1,089	974	1,859
All	1,570	1,519	1,399	1,055	1,527	1,712	1,692	1,322	1,107	1,662	1,626	1,593	1,364	1,080	1,582
OTHER															
0-19	2,147	2,369	*	*	2,221	2,050	2,446	*	1,655	2,176	2,104	2,405	1,639	2,081	2,200
20-29	1,438	1,590	1,613	1,234	1,493	2,093	2,325	1,755	1,827	2,178	1,742	1,974	1,693	1,578	1,831
30-39	1,490	1,924	2,338	943	1,682	1,727	2,131	1,543	1,932	1,917	1,598	2,023	1,948	1,511	1,792
40-49	1,504	1,683	1,338	1,289	1,582	1,727	2,003	1,476	1,327	1,834	1,606	1,824	1,390	1,310	1,696
50-59	1,610	1,572	1,435	1,185	1,581	1,840	1,732	2,611	1,504	1,798	1,726	1,648	1,982	1,364	1,688
60-64	1,797	1,854	2,102	1,398	1,809	1,931	1,845	1,519	1,427	1,883	1,865	1,849	1,855	1,413	1,847
65-69	1,706	1,836	2,194	1,201	1,727	1,899	1,937	2,042	1,797	1,908	1,800	1,890	2,111	1,508	1,818
70-79	1,682	1,691	2,005	1,131	1,672	1,848	2,114	1,585	1,482	1,893	1,758	1,913	1,768	1,323	1,777
80+	1,829	2,096	900	1,804	1,861	2,024	2,285	2,565	1,388	2,062	1,912	2,197	1,657	1,602	1,951
All	1,653	1,747	1,723	1,256	1,674	1,868	2,017	1,843	1,563	1,908	1,754	1,879	1,780	1,424	1,786
ALL															
0-19	2,114	2,128	*	1,757	2,100	2,095	2,232	1,285	1,286	2,106	2,106	2,180	1,360	1,513	2,103
20-29	1,632	1,503	1,364	1,219	1,549	2,050	2,155	1,465	1,453	2,064	1,822	1,796	1,421	1,333	1,784
30-39	1,847	1,777	1,843	971	1,787	1,981	2,073	1,855	1,645	2,013	1,900	1,901	1,848	1,291	1,880
40-49	1,809	1,675	1,661	1,170	1,715	1,976	2,001	1,939	1,365	1,964	1,876	1,802	1,772	1,264	1,814
50-59	1,859	1,664	1,905	1,399	1,753	2,144	1,989	2,055	1,518	2,043	1,985	1,813	1,979	1,458	1,885
60-64	1,976	1,747	2,007	1,424	1,864	2,185	1,940	2,097	1,572	2,045	2,076	1,853	2,055	1,500	1,957
65-69	1,917	1,769	1,968	1,337	1,846	2,146	2,053	2,038	1,577	2,084	2,031	1,938	2,013	1,466	1,975
70-79	1,922	1,837	1,918	1,363	1,883	2,110	2,166	1,879	1,410	2,100	2,010	2,043	1,894	1,389	1,996
80+	1,951	2,129	2,157	1,592	1,971	2,236	2,406	2,034	1,392	2,253	2,080	2,305	2,074	1,485	2,113
All	1,894	1,737	1,861	1,330	1,815	2,120	2,076	1,970	1,473	2,074	1,997	1,910	1,920	1,404	1,940

* Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

On our website: counts of total admissions and years at risk used to compute total admission rates (Table E.9.1).

Table E.10
Total Admissions per 1,000 Patient Years: All Dialysis Patients, 1997-1999
period prevalent patients

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	*	*	3,848	.	*	3,706	*	3,270	.	*	2,937
20-29	2,788	3,331	*	1,233	2,960	3,368	3,776	2,130	2,978	3,504	3,081	3,589	2,378	1,946	3,253
30-39	2,721	2,775	1,822	1,419	2,697	2,986	2,912	2,606	2,743	2,941	2,817	2,843	2,220	2,115	2,797
40-49	2,361	2,164	2,104	1,630	2,264	2,621	2,463	2,185	1,950	2,515	2,463	2,313	2,138	1,779	2,374
50-59	2,148	1,999	1,924	1,585	2,062	2,480	2,254	2,088	1,871	2,336	2,298	2,140	2,009	1,711	2,198
60-64	2,181	1,922	1,987	1,485	2,053	2,388	2,130	2,039	1,584	2,230	2,287	2,050	2,016	1,537	2,152
65-69	2,181	1,923	2,123	1,581	2,072	2,306	2,151	2,037	1,743	2,212	2,250	2,075	2,068	1,671	2,156
70-79	2,181	1,954	2,018	1,571	2,094	2,349	2,266	1,981	1,629	2,277	2,273	2,170	1,992	1,606	2,204
80+	2,340	2,220	2,121	1,496	2,252	2,549	2,484	2,263	1,829	2,483	2,456	2,409	2,229	1,674	2,394
All	2,250	2,050	2,009	1,558	2,152	2,438	2,282	2,079	1,757	2,336	2,344	2,192	2,049	1,665	2,253
HYPERTENSION															
0-19	1,678	1,095	*	.	1,363	1,264	2,280	*	*	1,910	1,491	1,642	*	*	1,619
20-29	1,440	1,346	1,870	1,029	1,362	1,484	1,549	2,032	632	1,518	1,460	1,409	1,959	886	1,416
30-39	1,488	1,632	1,896	1,256	1,601	1,481	1,817	1,237	1,241	1,730	1,485	1,694	1,702	1,250	1,644
40-49	1,535	1,518	1,744	1,008	1,514	1,668	1,694	1,376	1,442	1,677	1,578	1,575	1,617	1,196	1,567
50-59	1,715	1,475	1,879	1,371	1,540	1,952	1,756	1,432	1,408	1,791	1,803	1,583	1,677	1,389	1,636
60-64	1,921	1,572	1,524	1,262	1,692	2,120	1,722	2,113	1,436	1,838	2,000	1,643	1,845	1,339	1,757
65-69	1,857	1,652	2,443	1,179	1,751	2,165	1,894	2,037	1,336	1,987	1,985	1,779	2,221	1,264	1,863
70-79	1,920	1,761	1,759	1,362	1,857	2,158	2,084	1,967	1,238	2,094	2,017	1,954	1,883	1,303	1,971
80+	1,951	2,174	2,677	1,447	1,981	2,223	2,297	2,165	1,096	2,207	2,070	2,252	2,320	1,258	2,093
All	1,855	1,599	1,888	1,291	1,710	2,107	1,903	1,823	1,272	1,965	1,957	1,736	1,856	1,282	1,820
GLOMERULONEPHRITIS															
0-19	1,945	1,835	*	1,205	1,856	1,942	2,209	1,840	967	2,018	1,944	2,013	1,728	1,105	1,932
20-29	1,509	1,363	1,393	1,137	1,418	1,664	1,724	1,041	1,052	1,645	1,575	1,519	1,231	1,098	1,516
30-39	1,337	1,499	1,293	831	1,383	1,607	1,652	1,391	1,113	1,595	1,443	1,563	1,346	951	1,470
40-49	1,403	1,587	1,587	999	1,471	1,515	1,654	1,709	931	1,529	1,446	1,611	1,624	965	1,493
50-59	1,514	1,518	1,239	1,179	1,494	1,741	1,592	2,069	1,218	1,659	1,605	1,547	1,576	1,198	1,561
60-64	1,750	1,553	1,084	1,303	1,665	1,797	1,561	2,141	2,100	1,732	1,768	1,557	1,633	1,651	1,693
65-69	1,743	1,751	1,475	1,270	1,725	1,820	1,756	1,127	1,098	1,753	1,774	1,754	1,279	1,178	1,737
70-79	1,681	1,639	2,110	1,101	1,656	1,854	1,808	1,303	1,096	1,798	1,749	1,726	1,733	1,099	1,715
80+	1,821	2,095	1,209	1,391	1,829	2,051	2,152	1,973	1,102	2,022	1,919	2,127	1,653	1,251	1,915
All	1,582	1,552	1,460	1,084	1,547	1,753	1,696	1,546	1,121	1,692	1,650	1,613	1,500	1,102	1,607
OTHER															
0-19	2,173	2,175	1,434	2,482	2,173	2,174	2,374	2,595	1,202	2,213	2,173	2,266	2,061	1,765	2,190
20-29	1,477	1,711	1,543	1,330	1,561	2,026	2,309	2,484	1,518	2,128	1,734	2,021	2,055	1,438	1,841
30-39	1,518	1,874	2,101	943	1,668	1,812	2,110	1,640	1,389	1,927	1,656	1,990	1,875	1,208	1,793
40-49	1,508	1,679	1,347	1,071	1,573	1,679	1,997	1,470	1,254	1,799	1,588	1,820	1,399	1,171	1,676
50-59	1,651	1,593	1,292	1,391	1,617	1,820	1,818	2,302	1,283	1,807	1,736	1,702	1,771	1,331	1,712
60-64	1,702	1,721	2,137	1,192	1,697	1,837	1,901	2,247	1,559	1,857	1,772	1,818	2,191	1,367	1,782
65-69	1,713	1,793	1,956	1,245	1,723	1,926	1,972	2,277	1,412	1,926	1,821	1,891	2,127	1,337	1,828
70-79	1,745	1,760	2,143	1,296	1,740	1,922	2,062	1,666	1,564	1,942	1,826	1,920	1,875	1,441	1,836
80+	1,862	2,081	1,718	1,699	1,889	2,067	2,315	2,391	1,670	2,112	1,949	2,209	2,056	1,685	1,989
All	1,678	1,743	1,713	1,272	1,688	1,880	2,025	1,969	1,418	1,915	1,773	1,883	1,840	1,352	1,798
ALL															
0-19	2,097	1,980	1,559	1,845	2,041	2,087	2,333	2,210	1,111	2,148	2,093	2,146	1,980	1,466	2,089
20-29	1,627	1,574	1,594	1,187	1,585	2,047	2,131	1,817	1,287	2,049	1,819	1,821	1,714	1,235	1,795
30-39	1,852	1,791	1,758	1,009	1,796	2,047	2,046	1,792	1,474	2,020	1,931	1,898	1,774	1,234	1,889
40-49	1,796	1,671	1,844	1,152	1,712	1,967	1,963	1,902	1,307	1,936	1,865	1,785	1,867	1,228	1,801
50-59	1,866	1,668	1,800	1,428	1,757	2,131	1,982	2,048	1,516	2,035	1,984	1,814	1,924	1,470	1,884
60-64	1,978	1,733	1,894	1,361	1,853	2,168	1,954	2,066	1,608	2,046	2,070	1,854	1,989	1,482	1,952
65-69	1,949	1,788	2,100	1,400	1,878	2,158	2,037	2,002	1,531	2,081	2,053	1,937	2,039	1,472	1,988
70-79	1,929	1,821	1,993	1,395	1,886	2,159	2,156	1,911	1,457	2,128	2,036	2,031	1,940	1,429	2,011
80+	1,973	2,163	2,053	1,495	1,991	2,247	2,354	2,228	1,413	2,248	2,098	2,286	2,172	1,452	2,122
All	1,901	1,740	1,875	1,334	1,820	2,136	2,060	1,982	1,458	2,075	2,008	1,904	1,933	1,398	1,943

* Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

On our website: counts of total admissions and years at risk used to compute total admission rates (Table E.10.1).

Table E.11

Total Admissions per 1,000 Patient Years: All Hemodialysis Patients, 1999

period prevalent patients

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	*	*	*	.	.	*	*	*	.	.	*
20-29	2,948	3,333	.	.	3,062	3,415	4,053	.	.	3,694	3,161	3,763	2,287	.	3,396
30-39	2,808	2,673	2,119	915	2,717	2,978	2,981	3,090	1,983	2,947	2,865	2,825	2,580	1,492	2,808
40-49	2,380	2,200	1,924	1,579	2,271	2,576	2,435	2,176	1,842	2,472	2,456	2,317	2,032	1,694	2,359
50-59	2,107	1,981	2,010	1,567	2,035	2,434	2,245	1,989	1,856	2,303	2,254	2,124	1,999	1,702	2,168
60-64	2,134	1,912	2,163	1,557	2,032	2,350	2,105	2,069	1,494	2,194	2,244	2,031	2,112	1,521	2,123
65-69	2,142	1,885	2,077	1,587	2,028	2,310	2,139	2,072	1,715	2,208	2,238	2,052	2,074	1,657	2,137
70-79	2,182	2,001	2,078	1,555	2,105	2,292	2,213	1,928	1,545	2,221	2,243	2,147	1,980	1,549	2,175
80+	2,267	2,188	2,533	1,663	2,212	2,563	2,528	2,079	1,869	2,507	2,430	2,429	2,202	1,774	2,391
All	2,226	2,037	2,056	1,553	2,132	2,393	2,260	2,052	1,685	2,298	2,310	2,174	2,054	1,625	2,224
HYPERTENSION															
0-19	*	881	.	.	1,322	*	1,533	.	.	1,789	*	1,164	.	.	1,514
20-29	1,785	1,218	*	1,116	1,309	1,655	1,611	*	*	1,609	1,730	1,336	1,083	1,155	1,406
30-39	1,373	1,627	1,516	1,491	1,580	1,627	1,868	*	1,043	1,817	1,460	1,705	1,938	1,329	1,658
40-49	1,472	1,500	1,365	936	1,484	1,596	1,816	1,619	1,824	1,775	1,511	1,599	1,451	1,325	1,576
50-59	1,721	1,464	1,561	1,365	1,525	2,108	1,758	1,814	1,349	1,830	1,861	1,572	1,670	1,358	1,638
60-64	1,804	1,548	993	1,050	1,618	2,162	1,648	2,325	1,841	1,808	1,947	1,594	1,785	1,363	1,702
65-69	1,768	1,607	1,861	945	1,669	2,106	1,912	2,264	1,340	1,968	1,909	1,766	2,085	1,161	1,812
70-79	1,916	1,783	1,596	1,357	1,858	2,079	2,147	2,102	1,181	2,081	1,984	2,003	1,895	1,271	1,967
80+	1,967	2,096	3,058	1,646	1,986	2,224	2,356	2,185	1,102	2,227	2,079	2,259	2,471	1,351	2,104
All	1,843	1,582	1,553	1,291	1,690	2,094	1,950	2,064	1,296	1,989	1,946	1,746	1,803	1,293	1,819
GLOMERULONEPHRITIS															
0-19	1,866	1,922	*	*	1,859	2,543	1,835	*	*	1,980	2,115	1,883	*	1,150	1,910
20-29	1,460	1,282	1,285	1,283	1,359	1,704	1,637	1,047	999	1,618	1,555	1,433	1,173	1,161	1,465
30-39	1,263	1,441	1,462	816	1,328	1,579	1,709	1,553	1,274	1,629	1,374	1,548	1,498	993	1,442
40-49	1,442	1,604	1,352	862	1,494	1,469	1,751	1,417	1,099	1,573	1,452	1,652	1,371	966	1,521
50-59	1,490	1,464	1,327	1,153	1,461	1,694	1,524	2,354	1,215	1,610	1,569	1,487	1,756	1,182	1,519
60-64	1,769	1,450	1,353	1,796	1,656	1,667	1,558	1,782	1,650	1,627	1,730	1,498	1,556	1,732	1,644
65-69	1,720	1,611	1,619	1,029	1,670	1,682	1,896	838	1,090	1,693	1,704	1,754	1,194	1,062	1,680
70-79	1,620	1,542	1,803	1,160	1,593	1,928	1,688	1,058	1,087	1,815	1,738	1,619	1,449	1,122	1,685
80+	1,737	2,129	*	972	1,741	2,071	2,206	*	1,008	2,021	1,876	2,171	872	990	1,864
All	1,552	1,509	1,412	1,058	1,513	1,754	1,699	1,422	1,150	1,692	1,629	1,586	1,416	1,100	1,584
OTHER															
0-19	1,808	1,984	*	*	1,876	1,942	1,828	*	*	1,867	1,867	1,908	1,705	*	1,872
20-29	1,399	1,662	1,663	1,273	1,501	2,008	2,233	1,934	1,773	2,102	1,659	1,955	1,808	1,547	1,784
30-39	1,442	1,932	2,582	762	1,669	1,782	2,097	1,769	2,093	1,940	1,590	2,007	2,206	1,467	1,790
40-49	1,500	1,649	1,267	1,388	1,568	1,735	1,994	1,332	1,451	1,844	1,602	1,793	1,287	1,421	1,686
50-59	1,596	1,557	1,266	1,114	1,561	1,889	1,779	2,422	1,420	1,836	1,739	1,659	1,822	1,280	1,693
60-64	1,840	1,810	2,181	1,447	1,824	1,957	1,841	1,044	1,546	1,894	1,898	1,827	1,691	1,498	1,859
65-69	1,725	1,800	2,194	1,232	1,734	1,930	1,949	2,113	1,848	1,935	1,824	1,880	2,153	1,545	1,835
70-79	1,696	1,699	1,957	1,216	1,687	1,862	2,127	1,766	1,525	1,913	1,773	1,924	1,855	1,386	1,795
80+	1,829	2,097	*	1,881	1,863	2,032	2,318	2,506	1,347	2,075	1,915	2,214	1,552	1,618	1,958
All	1,650	1,729	1,719	1,273	1,668	1,888	2,005	1,872	1,586	1,919	1,759	1,861	1,789	1,439	1,785
ALL															
0-19	1,832	1,866	*	1,803	1,837	2,113	1,852	*	969	1,923	1,948	1,860	1,405	1,376	1,875
20-29	1,612	1,478	1,415	1,230	1,528	2,055	2,116	1,492	1,526	2,055	1,796	1,755	1,455	1,366	1,754
30-39	1,801	1,775	1,909	935	1,765	2,021	2,083	2,251	1,644	2,045	1,884	1,898	2,049	1,252	1,874
40-49	1,802	1,665	1,634	1,172	1,704	1,978	2,019	1,914	1,509	1,982	1,869	1,798	1,740	1,327	1,810
50-59	1,843	1,648	1,840	1,365	1,731	2,162	1,976	2,033	1,547	2,043	1,983	1,796	1,935	1,452	1,871
60-64	1,974	1,728	2,004	1,451	1,851	2,188	1,923	2,026	1,568	2,032	2,076	1,834	2,016	1,511	1,944
65-69	1,919	1,750	2,022	1,330	1,839	2,156	2,043	2,018	1,583	2,083	2,038	1,924	2,019	1,467	1,972
70-79	1,918	1,838	1,952	1,391	1,880	2,116	2,159	1,898	1,396	2,102	2,012	2,040	1,918	1,394	1,997
80+	1,958	2,121	2,130	1,603	1,976	2,252	2,407	2,035	1,382	2,264	2,091	2,303	2,065	1,486	2,122
All	1,887	1,726	1,856	1,336	1,805	2,135	2,072	1,980	1,488	2,080	2,000	1,901	1,922	1,414	1,937

* Values for cells with fewer than 10 patients are suppressed.

"." Zero patients in this cell.

On our website: counts of total admissions and years at risk used to compute total admission rates (Table E.11.1).

Table E.12
Total Admissions per 1,000 Patient Years: All Hemodialysis Patients, 1997-1999
period prevalent patients

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	*	*	*	.	*	3,665	*	3,132	.	*	2,795
20-29	2,678	3,338	*	551	2,879	3,726	3,755	1,870	*	3,682	3,174	3,586	1,997	1,475	3,305
30-39	2,708	2,774	1,830	1,348	2,684	3,034	2,910	2,765	2,498	2,957	2,819	2,840	2,300	1,945	2,792
40-49	2,368	2,147	2,032	1,633	2,251	2,624	2,398	2,146	1,936	2,478	2,467	2,271	2,079	1,770	2,350
50-59	2,114	1,966	1,868	1,525	2,023	2,421	2,215	2,058	1,840	2,286	2,253	2,103	1,965	1,667	2,154
60-64	2,140	1,886	1,968	1,424	2,009	2,365	2,100	2,021	1,543	2,199	2,257	2,018	1,998	1,487	2,117
65-69	2,160	1,902	2,186	1,657	2,052	2,281	2,126	1,998	1,737	2,185	2,228	2,051	2,063	1,701	2,133
70-79	2,160	1,943	2,011	1,559	2,072	2,337	2,246	1,993	1,594	2,261	2,258	2,154	1,998	1,580	2,188
80+	2,333	2,197	2,099	1,508	2,241	2,549	2,486	2,229	1,865	2,485	2,454	2,402	2,197	1,696	2,391
All	2,222	2,022	1,981	1,543	2,121	2,411	2,250	2,058	1,727	2,304	2,318	2,162	2,025	1,642	2,222
HYPERTENSION															
0-19	1,730	1,088	*	.	1,341	2,007	1,970	*	.	2,036	1,841	1,451	*	.	1,625
20-29	1,406	1,314	1,865	946	1,329	1,607	1,579	2,119	708	1,580	1,488	1,391	1,972	877	1,409
30-39	1,472	1,616	1,891	1,151	1,585	1,455	1,801	1,593	1,365	1,726	1,466	1,675	1,827	1,219	1,631
40-49	1,544	1,506	1,806	908	1,506	1,672	1,706	1,513	1,398	1,690	1,584	1,569	1,711	1,116	1,564
50-59	1,685	1,453	1,758	1,451	1,513	1,987	1,723	1,410	1,509	1,775	1,793	1,554	1,596	1,476	1,611
60-64	1,894	1,568	1,352	1,308	1,672	2,115	1,700	2,128	1,545	1,816	1,980	1,629	1,773	1,410	1,736
65-69	1,851	1,629	2,189	1,088	1,727	2,196	1,879	1,934	1,380	1,984	1,995	1,761	2,050	1,246	1,850
70-79	1,915	1,758	1,744	1,369	1,851	2,162	2,074	1,961	1,217	2,090	2,017	1,947	1,875	1,295	1,967
80+	1,965	2,159	2,628	1,444	1,991	2,228	2,287	2,158	1,084	2,207	2,081	2,241	2,300	1,250	2,099
All	1,855	1,588	1,838	1,283	1,700	2,126	1,898	1,854	1,283	1,970	1,965	1,727	1,846	1,283	1,816
GLOMERULONEPHRITIS															
0-19	1,890	1,734	*	1,274	1,774	2,003	1,986	1,334	537	1,913	1,934	1,845	1,203	1,010	1,833
20-29	1,486	1,327	1,424	1,202	1,392	1,705	1,604	1,048	1,193	1,612	1,570	1,440	1,272	1,198	1,479
30-39	1,307	1,450	1,245	866	1,351	1,607	1,663	1,656	1,061	1,609	1,415	1,533	1,427	939	1,448
40-49	1,399	1,604	1,605	965	1,483	1,534	1,705	1,436	1,001	1,570	1,447	1,638	1,559	981	1,513
50-59	1,491	1,488	1,177	1,180	1,469	1,770	1,585	1,964	1,271	1,673	1,601	1,526	1,503	1,222	1,550
60-64	1,751	1,544	1,216	1,364	1,661	1,787	1,589	2,240	2,210	1,743	1,765	1,564	1,760	1,737	1,695
65-69	1,746	1,691	1,464	1,192	1,711	1,848	1,771	1,136	1,017	1,769	1,787	1,731	1,281	1,099	1,736
70-79	1,656	1,649	2,042	1,161	1,638	1,873	1,795	1,321	1,102	1,807	1,741	1,724	1,712	1,132	1,709
80+	1,818	2,090	1,069	1,373	1,824	2,080	2,159	1,968	1,159	2,049	1,930	2,129	1,590	1,269	1,925
All	1,569	1,534	1,436	1,100	1,534	1,784	1,694	1,573	1,163	1,713	1,652	1,598	1,494	1,129	1,605
OTHER															
0-19	2,002	1,938	1,256	3,702	1,992	2,094	2,001	1,731	1,075	2,016	2,041	1,967	1,494	2,099	2,002
20-29	1,473	1,693	1,609	1,407	1,558	2,040	2,262	2,357	1,582	2,125	1,719	1,979	1,962	1,502	1,823
30-39	1,481	1,856	2,413	827	1,649	1,829	2,070	1,853	1,367	1,929	1,632	1,955	2,152	1,120	1,776
40-49	1,496	1,675	1,302	1,091	1,570	1,688	1,962	1,501	1,372	1,801	1,581	1,795	1,380	1,234	1,670
50-59	1,623	1,568	1,229	1,309	1,587	1,850	1,821	2,243	1,247	1,822	1,734	1,686	1,680	1,275	1,700
60-64	1,709	1,675	2,312	1,240	1,688	1,837	1,891	2,226	1,752	1,860	1,774	1,791	2,270	1,471	1,777
65-69	1,725	1,769	2,002	1,265	1,726	1,933	1,945	2,148	1,520	1,926	1,829	1,865	2,074	1,401	1,829
70-79	1,736	1,748	2,138	1,309	1,732	1,926	2,043	1,780	1,588	1,943	1,823	1,906	1,940	1,464	1,833
80+	1,863	2,045	1,631	1,826	1,889	2,064	2,303	2,374	1,646	2,108	1,948	2,186	2,023	1,738	1,988
All	1,666	1,720	1,757	1,284	1,675	1,892	1,996	1,980	1,474	1,917	1,770	1,854	1,863	1,384	1,789
ALL															
0-19	1,957	1,785	1,323	2,246	1,880	2,078	2,034	1,598	893	2,005	2,007	1,897	1,494	1,567	1,934
20-29	1,596	1,538	1,600	1,203	1,553	2,122	2,094	1,765	1,408	2,073	1,817	1,773	1,677	1,296	1,773
30-39	1,802	1,766	1,805	979	1,760	2,048	2,034	2,061	1,477	2,022	1,895	1,872	1,916	1,195	1,863
40-49	1,790	1,664	1,824	1,140	1,703	1,986	1,956	1,893	1,382	1,945	1,866	1,774	1,850	1,253	1,796
50-59	1,839	1,641	1,738	1,406	1,725	2,132	1,960	2,009	1,538	2,022	1,969	1,788	1,872	1,468	1,859
60-64	1,956	1,710	1,888	1,358	1,826	2,164	1,936	2,057	1,650	2,031	2,057	1,833	1,981	1,500	1,932
65-69	1,944	1,763	2,116	1,411	1,864	2,161	2,018	1,953	1,553	2,072	2,053	1,915	2,014	1,488	1,977
70-79	1,918	1,815	1,976	1,406	1,875	2,162	2,141	1,936	1,440	2,123	2,033	2,020	1,950	1,425	2,006
80+	1,980	2,143	1,995	1,515	1,994	2,252	2,349	2,207	1,424	2,251	2,105	2,275	2,140	1,467	2,125
All	1,889	1,722	1,857	1,338	1,803	2,146	2,046	1,982	1,480	2,074	2,006	1,887	1,924	1,410	1,934

* Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

On our website: counts of total admissions and years at risk used to compute total admission rates (Table E.12.1).

Table E.13

Total Admissions per 1,000 Patient Years: All CAPD/CCPD Patients, 1999*period prevalent patients*

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	.	.	*	.	*	.	.	*
20-29	3,601	4,884	.	.	4,047	3,151	3,041	*	*	3,141	3,312	3,806	.	*	3,475
30-39	2,682	2,062	*	*	2,542	2,705	2,883	*	*	2,760	2,692	2,516	1,905	*	2,639
40-49	2,358	2,320	2,664	*	2,333	2,667	3,021	2,849	*	2,735	2,489	2,692	2,766	949	2,514
50-59	2,268	2,275	2,328	2,312	2,274	2,731	2,722	2,308	1,837	2,675	2,469	2,549	2,317	2,094	2,472
60-64	2,335	2,309	1,733	*	2,300	2,536	2,513	2,909	1,991	2,525	2,431	2,425	2,469	1,935	2,416
65-69	2,135	2,163	*	1,237	2,074	2,488	2,463	*	2,161	2,463	2,303	2,356	1,483	1,701	2,274
70-79	2,343	2,050	*	1,502	2,249	2,337	2,690	1,895	2,153	2,398	2,340	2,450	1,307	1,905	2,320
80+	2,550	*	.	*	2,641	2,206	3,202	.	*	2,291	2,372	3,492	.	1,330	2,445
All	2,355	2,300	1,831	1,613	2,311	2,570	2,716	2,445	2,024	2,588	2,451	2,548	2,180	1,841	2,446
HYPERTENSION															
0-19	*	*	.	.	*	*	*	.	.	*	*	*	.	.	*
20-29	1,194	1,699	.	*	1,565	866	1,465	*	*	1,200	1,001	1,603	*	1,375	1,380
30-39	1,979	1,701	*	*	1,794	1,560	1,779	*	*	1,619	1,800	1,735	*	1,385	1,717
40-49	1,296	1,709	*	1,758	1,592	2,057	1,425	*	921	1,573	1,611	1,583	1,527	1,381	1,584
50-59	1,949	1,790	3,180	809	1,857	1,906	2,062	*	1,045	1,943	1,932	1,920	2,657	952	1,895
60-64	1,647	1,449	*	*	1,608	2,290	1,937	*	981	2,039	1,945	1,757	*	987	1,840
65-69	1,654	1,990	*	*	1,717	2,040	1,954	*	914	1,989	1,819	1,970	*	1,136	1,843
70-79	1,952	1,948	*	1,099	1,907	2,060	2,209	*	1,384	2,065	1,997	2,091	*	1,205	1,975
80+	1,705	2,173	*	1,533	1,722	1,886	2,824	*	*	1,967	1,777	2,549	*	1,679	1,825
All	1,782	1,755	2,707	1,357	1,765	1,978	1,846	1,547	1,086	1,873	1,864	1,799	2,118	1,220	1,813
GLOMERULONEPHRITIS															
0-19	1,914	2,295	.	*	1,960	2,083	2,179	*	*	2,057	2,003	2,210	*	*	2,019
20-29	1,365	1,710	*	903	1,435	1,606	2,112	*	760	1,727	1,498	1,954	741	832	1,601
30-39	1,545	1,706	.	519	1,528	1,392	1,583	695	1,659	1,451	1,464	1,624	695	1,121	1,482
40-49	1,568	1,467	*	928	1,480	1,411	1,360	*	725	1,330	1,493	1,409	1,363	804	1,404
50-59	1,493	1,581	*	1,227	1,490	1,410	1,568	*	625	1,387	1,453	1,574	*	878	1,438
60-64	1,851	1,793	*	*	1,781	1,696	1,702	*	*	1,697	1,785	1,733	*	*	1,740
65-69	1,980	2,429	.	*	2,021	1,561	1,760	*	*	1,615	1,793	1,980	*	2,043	1,830
70-79	1,732	944	*	686	1,674	1,772	1,465	*	*	1,709	1,747	1,219	*	904	1,687
80+	1,689	*	*	.	1,759	1,663	*	*	*	1,617	1,678	*	*	*	1,697
All	1,650	1,624	1,297	990	1,604	1,546	1,651	967	936	1,529	1,602	1,640	1,086	961	1,566
OTHER															
0-19	2,537	3,026	.	*	2,659	1,942	3,383	*	*	2,392	2,269	3,183	*	*	2,537
20-29	1,724	1,227	*	*	1,537	2,373	2,777	*	1,982	2,465	2,105	2,162	*	1,695	2,093
30-39	1,802	1,849	*	1,955	1,805	1,578	2,347	*	1,845	1,898	1,678	2,175	756	1,879	1,861
40-49	1,469	2,038	*	858	1,644	1,731	2,056	1,756	965	1,808	1,621	2,049	1,756	924	1,741
50-59	1,582	1,752	*	*	1,652	1,564	1,324	*	2,004	1,532	1,571	1,487	3,353	2,078	1,583
60-64	1,388	3,310	*	*	1,642	1,860	2,004	*	*	1,909	1,668	2,409	*	*	1,804
65-69	1,615	2,201	.	*	1,664	1,712	1,898	*	*	1,724	1,665	2,059	*	1,269	1,695
70-79	1,557	1,477	*	520	1,517	1,691	1,781	*	1,095	1,647	1,615	1,635	*	812	1,575
80+	1,816	*	*	*	1,788	1,822	*	*	*	1,796	1,818	1,328	*	*	1,792
All	1,656	1,970	1,795	1,066	1,709	1,754	2,118	1,702	1,536	1,845	1,708	2,059	1,739	1,354	1,784
ALL															
0-19	2,354	2,833	.	*	2,461	1,967	2,800	*	*	2,257	2,172	2,815	*	1,302	2,358
20-29	1,724	1,805	*	1,177	1,714	2,069	2,345	1,488	1,279	2,110	1,925	2,112	1,351	1,235	1,943
30-39	2,110	1,793	1,156	1,262	1,963	1,861	2,061	915	1,760	1,911	1,989	1,949	975	1,558	1,935
40-49	1,834	1,822	1,958	1,046	1,800	1,990	1,853	2,021	872	1,875	1,908	1,838	1,993	945	1,837
50-59	1,925	1,896	2,387	1,700	1,921	2,009	2,101	2,287	1,319	2,020	1,965	2,010	2,340	1,486	1,971
60-64	1,965	2,073	2,038	1,307	1,969	2,219	2,147	3,005	1,535	2,187	2,090	2,118	2,578	1,437	2,085
65-69	1,878	2,134	1,176	1,390	1,890	2,062	2,192	2,521	1,696	2,084	1,965	2,169	1,877	1,537	1,986
70-79	1,952	1,833	1,287	1,037	1,900	2,029	2,333	1,520	1,626	2,057	1,984	2,121	1,436	1,329	1,970
80+	1,848	2,606	*	1,317	1,874	1,903	2,619	*	1,571	1,957	1,872	2,614	*	1,469	1,911
All	1,929	1,907	1,889	1,256	1,898	2,020	2,112	1,899	1,393	2,017	1,971	2,022	1,895	1,332	1,958

* Values for cells with fewer than 10 patients are suppressed.

"." Zero patients in this cell.

On our website: counts of total admissions and years at risk used to compute total admission rates (Table E.13.1).

Table E.14
Total Admissions per 1,000 Years: All CAPD/CCPD Patients, 1997-1999
period prevalent patients

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19
20-29	2,996	3,362	*	*	3,171	2,616	3,868	*	*	2,921	2,769	3,628	*	*	3,026
30-39	2,725	2,781	1,342	2,151	2,711	2,850	2,918	1,903	4,629	2,870	2,777	2,860	1,662	3,686	2,783
40-49	2,309	2,356	2,810	1,738	2,322	2,581	3,023	2,406	2,030	2,683	2,422	2,718	2,592	1,913	2,485
50-59	2,304	2,374	2,215	1,986	2,306	2,825	2,699	2,327	2,116	2,736	2,533	2,558	2,281	2,037	2,513
60-64	2,441	2,327	2,235	1,995	2,394	2,576	2,627	2,306	1,792	2,550	2,505	2,500	2,276	1,884	2,473
65-69	2,315	2,330	1,437	1,090	2,243	2,502	2,549	2,863	1,892	2,493	2,402	2,468	2,198	1,491	2,369
70-79	2,352	2,237	2,196	1,702	2,316	2,532	2,852	1,936	2,040	2,564	2,431	2,613	2,026	1,917	2,436
80+	2,456	3,452	*	1,158	2,479	2,465	2,361	*	737	2,353	2,461	2,639	*	890	2,407
All	2,396	2,411	2,215	1,712	2,374	2,635	2,772	2,342	2,021	2,642	2,503	2,621	2,289	1,875	2,504
HYPERTENSION															
0-19	*	*	.	.	1,470	*	*	.	*	1,224	1,029	1,916	.	*	1,324
20-29	1,504	1,670	*	1,282	1,595	1,219	1,352	1,925	541	1,288	1,345	1,523	1,925	905	1,437
30-39	1,642	1,775	*	1,708	1,730	1,561	1,847	*	1,025	1,702	1,609	1,806	628	1,270	1,718
40-49	1,489	1,625	1,335	1,366	1,567	1,659	1,576	904	1,423	1,582	1,556	1,605	1,147	1,392	1,573
50-59	1,871	1,735	2,579	821	1,774	1,785	2,013	*	1,155	1,864	1,834	1,867	1,918	1,027	1,816
60-64	2,090	1,602	*	1,058	1,894	2,192	1,902	*	995	2,000	2,134	1,775	2,813	1,023	1,947
65-69	1,851	2,099	*	1,801	1,916	1,948	2,115	*	1,001	1,972	1,891	2,108	4,254	1,379	1,941
70-79	1,944	1,854	*	1,321	1,908	2,089	2,299	2,492	1,476	2,114	2,000	2,096	2,006	1,381	1,993
80+	1,756	2,831	*	1,519	1,824	2,097	2,656	*	983	2,113	1,888	2,731	*	1,258	1,942
All	1,848	1,744	2,276	1,314	1,795	1,946	1,902	1,604	1,162	1,886	1,888	1,819	1,918	1,236	1,835
GLOMERULONEPHRITIS															
0-19	1,916	2,111	*	*	1,950	1,860	2,676	*	1,283	2,141	1,887	2,427	2,858	1,237	2,053
20-29	1,577	1,587	1,261	892	1,527	1,598	2,112	1,141	781	1,728	1,588	1,883	1,192	832	1,638
30-39	1,482	1,914	*	662	1,583	1,571	1,612	881	1,226	1,535	1,528	1,735	1,020	1,000	1,556
40-49	1,422	1,450	1,507	1,041	1,402	1,453	1,437	2,231	769	1,390	1,436	1,443	1,833	886	1,396
50-59	1,607	1,798	1,695	1,103	1,623	1,603	1,608	*	1,015	1,559	1,606	1,693	1,546	1,052	1,592
60-64	1,711	1,548	*	1,087	1,650	1,844	1,431	*	1,317	1,700	1,768	1,474	640	1,191	1,674
65-69	1,704	2,488	*	1,605	1,762	1,733	1,496	*	1,518	1,679	1,716	1,883	*	1,560	1,725
70-79	1,811	1,515	*	596	1,767	1,765	1,986	1,239	1,589	1,777	1,794	1,781	2,028	954	1,771
80+	1,843	2,192	*	*	1,873	1,700	*	*	*	1,625	1,787	2,020	*	944	1,777
All	1,633	1,703	1,670	985	1,615	1,633	1,690	1,343	1,005	1,602	1,633	1,695	1,473	996	1,609
OTHER															
0-19	2,342	2,450	*	1,443	2,345	2,119	2,910	*	1,408	2,358	2,251	2,669	*	1,424	2,351
20-29	1,505	1,736	*	961	1,544	1,977	2,503	2,823	1,362	2,119	1,780	2,208	2,454	1,233	1,890
30-39	1,631	1,962	637	1,181	1,702	1,785	2,302	1,010	1,519	1,948	1,724	2,181	858	1,415	1,855
40-49	1,542	1,712	1,643	898	1,575	1,638	2,131	1,386	931	1,769	1,597	1,962	1,502	920	1,688
50-59	1,730	1,856	1,476	2,126	1,766	1,688	1,771	2,596	1,413	1,715	1,706	1,803	2,177	1,653	1,736
60-64	1,668	2,399	*	588	1,759	1,857	2,050	*	635	1,865	1,779	2,192	1,696	616	1,821
65-69	1,627	2,035	*	1,170	1,662	1,840	2,294	2,848	1,005	1,878	1,741	2,177	2,523	1,071	1,779
70-79	1,789	1,829	2,178	1,152	1,772	1,793	2,084	1,010	1,094	1,785	1,791	1,960	1,504	1,127	1,777
80+	1,791	3,509	*	221	1,820	1,916	1,440	*	*	1,860	1,842	2,414	*	516	1,837
All	1,715	1,922	1,391	1,134	1,737	1,790	2,172	1,964	1,206	1,869	1,755	2,072	1,742	1,179	1,811
ALL															
0-19	2,221	2,322	*	1,346	2,222	1,997	2,814	4,053	1,331	2,257	2,122	2,575	3,685	1,337	2,239
20-29	1,726	1,805	1,555	1,113	1,721	1,879	2,263	2,005	1,035	1,969	1,813	2,060	1,884	1,067	1,862
30-39	2,045	1,989	1,098	1,086	1,983	2,033	2,092	1,092	1,513	2,004	2,039	2,046	1,094	1,361	1,994
40-49	1,810	1,727	2,000	1,159	1,757	1,894	1,975	1,914	1,059	1,877	1,850	1,853	1,957	1,101	1,816
50-59	1,973	1,965	2,141	1,545	1,958	2,104	2,152	2,207	1,399	2,095	2,035	2,066	2,177	1,466	2,027
60-64	2,104	2,009	1,964	1,451	2,058	2,216	2,163	2,265	1,352	2,169	2,159	2,099	2,130	1,397	2,115
65-69	1,958	2,220	2,008	1,324	1,975	2,104	2,305	2,825	1,482	2,133	2,025	2,270	2,480	1,407	2,052
70-79	2,002	1,960	2,201	1,264	1,974	2,114	2,488	1,732	1,676	2,158	2,048	2,261	1,919	1,461	2,054
80+	1,872	2,939	*	1,195	1,922	2,085	2,354	*	819	2,063	1,961	2,596	3,357	1,010	1,984
All	1,962	1,935	1,980	1,286	1,930	2,059	2,171	1,989	1,331	2,058	2,007	2,064	1,985	1,311	1,993

* Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

On our website: counts of total admissions and years at risk used to compute total admission rates (Table E.14.1).

Table E.15

Total Admissions per 1,000 Patient Years: All Transplant Patients, 1999*period prevalent patients; first three years after transplant*

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	.	.	.	*	*	.	.	.	*	*	.	.	.	*
20-29	1,119	1,324	.	.	1,168	1,141	1,266	*	.	1,176	1,130	1,291	*	.	1,172
30-39	935	1,343	*	*	980	1,291	1,505	*	*	1,347	1,086	1,420	1,911	765	1,139
40-49	884	1,184	1,616	207	929	1,124	1,435	381	1,130	1,157	975	1,280	1,049	597	1,016
50-59	881	1,082	957	580	919	973	1,415	1,475	859	1,147	912	1,238	1,200	663	1,006
60-64	921	1,214	212	0	943	977	1,367	103	628	1,042	940	1,280	157	310	980
65-69	710	1,100	*	*	829	1,168	1,774	*	*	1,323	883	1,385	*	808	1,019
70-79	910	1,265	*	*	936	1,078	1,851	.	*	1,400	946	1,535	*	*	1,061
80+	*	.	.	.	*	*	.	.	.	*
All	897	1,180	1,040	362	941	1,133	1,452	1,167	953	1,206	986	1,302	1,098	592	1,046
HYPERTENSION															
0-19	*	*	.	.	*	*	*	.	*	1,924	2,003	*	.	*	1,258
20-29	518	783	*	*	642	818	926	*	*	902	619	831	*	241	730
30-39	572	703	*	350	641	725	779	*	654	754	618	726	*	444	676
40-49	595	701	581	235	642	621	851	*	532	759	603	748	848	368	680
50-59	574	724	*	498	662	612	810	*	331	693	586	750	1,807	414	672
60-64	674	875	.	237	716	640	856	*	*	737	663	868	*	294	723
65-69	745	1,161	*	965	860	769	1,166	.	*	880	753	1,163	*	676	867
70-79	944	1,186	.	*	980	1,318	826	.	*	1,115	1,033	1,025	.	*	1,018
80+	*	*	.	.	*	*	.	.	.	*	*	*	.	.	*
All	647	750	941	401	689	733	854	1,576	428	784	675	783	1,148	411	720
GLOMERULONEPHRITIS															
0-19	910	1,021	*	*	955	793	1,964	*	*	1,091	845	1,411	*	1,050	1,024
20-29	423	581	*	532	479	1,020	862	*	624	954	662	693	1,035	568	669
30-39	402	588	*	244	447	516	762	*	230	558	442	654	704	236	488
40-49	436	740	*	259	493	463	624	593	256	478	446	693	585	258	487
50-59	518	737	*	74	539	507	716	*	336	531	514	729	725	224	536
60-64	631	670	*	764	641	611	954	.	*	668	624	775	*	753	650
65-69	802	592	*	276	756	642	1,392	.	*	778	750	931	*	547	763
70-79	776	*	*	*	719	526	*	.	*	509	710	215	*	*	658
80+	*	.	.	.	*	*	.	.	.	*
All	507	671	637	338	536	616	845	724	368	648	547	739	677	353	579
OTHER															
0-19	814	1,199	*	875	902	900	1,178	*	*	985	849	1,191	*	1,153	935
20-29	603	762	*	550	627	816	1,105	*	696	868	701	918	*	617	737
30-39	578	657	*	245	588	804	858	*	581	810	692	771	1,023	456	704
40-49	532	885	*	580	598	561	869	*	499	626	545	876	466	530	611
50-59	491	691	*	1,117	544	585	725	*	724	612	536	708	479	889	577
60-64	752	999	*	130	780	502	1,064	*	686	602	631	1,023	1,129	426	696
65-69	808	1,080	*	*	835	789	1,170	*	*	842	799	1,119	*	102	838
70-79	773	1,717	.	*	828	1,060	504	.	*	995	877	1,072	.	*	891
80+	*	*	.	.	*	*	*	.	.	*
All	613	856	835	593	658	695	904	951	650	737	651	880	904	625	695
ALL															
0-19	836	1,106	*	905	910	902	1,454	*	1,320	1,034	865	1,240	1,119	1,080	963
20-29	579	734	495	490	617	931	1,002	1,294	662	943	732	846	908	559	757
30-39	646	755	830	273	664	903	938	1,662	477	899	754	833	1,213	381	764
40-49	632	817	953	309	673	726	895	580	445	750	669	848	784	379	704
50-59	632	814	1,003	521	684	668	990	1,187	507	759	646	884	1,095	514	714
60-64	763	1,000	293	270	792	658	1,112	533	656	769	723	1,044	418	420	783
65-69	769	1,049	1,938	522	821	850	1,389	*	575	965	800	1,195	2,243	540	877
70-79	846	1,145	*	649	872	1,010	1,020	.	*	994	893	1,087	*	618	910
80+	804	*	.	.	661	*	.	.	.	*	822	*	.	.	683
All	669	837	904	415	705	793	1,005	1,050	536	838	718	905	973	472	759

* Values for cells with fewer than 10 patients are suppressed.

"." Zero patients in this cell.

On our website: counts of total admissions and years at risk used to compute total admission rates (Table E.15.1).

Table E.16
Total Admissions per 1,000 Patient Years: All Transplant Patients, 1997-1999
period prevalent patients; first three years after transplant

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	*	*	.	.	.	*	*	*	.	.	548
20-29	1,306	1,578	*	.	1,353	1,249	1,721	*	*	1,417	1,277	1,666	*	*	1,387
30-39	1,049	1,310	711	848	1,076	1,192	1,448	2,205	1,244	1,240	1,110	1,377	1,384	1,096	1,147
40-49	940	1,281	1,141	308	981	1,138	1,381	1,118	1,094	1,171	1,014	1,319	1,130	662	1,053
50-59	982	1,121	853	543	996	1,037	1,388	1,318	1,198	1,170	1,001	1,240	1,050	764	1,061
60-64	974	1,172	971	453	1,005	1,168	1,304	1,049	456	1,173	1,045	1,231	1,013	454	1,072
65-69	810	1,155	2,337	623	901	1,125	1,429	*	*	1,202	921	1,267	1,923	798	1,011
70-79	871	1,101	*	388	890	786	1,550	*	*	1,070	851	1,250	*	406	936
80+	*	.	.	.	*	*	.	.	.	*
All	987	1,212	975	499	1,017	1,140	1,419	1,382	1,080	1,206	1,046	1,304	1,160	743	1,092
HYPERTENSION															
0-19	449	1,032	*	.	688	1,051	*	.	*	1,179	792	1,363	*	*	930
20-29	489	887	*	232	692	736	998	*	*	867	580	925	683	338	754
30-39	518	724	*	323	625	658	1,020	*	415	824	563	813	1,206	357	688
40-49	570	808	822	300	705	730	898	858	377	797	623	835	831	339	734
50-59	592	740	866	454	664	728	889	2,212	288	783	636	786	1,300	377	702
60-64	687	903	*	277	750	767	799	*	441	760	715	863	*	324	754
65-69	786	1,208	*	628	881	734	1,093	.	531	852	770	1,160	*	596	871
70-79	1,036	1,150	.	1,284	1,066	1,103	1,022	.	*	1,056	1,054	1,099	.	1,026	1,063
80+	*	*	.	.	419	*	.	.	.	*	*	*	.	.	465
All	635	808	1,003	400	712	751	935	1,007	370	818	673	848	1,005	388	747
GLOMERULONEPHRITIS															
0-19	802	919	*	864	844	824	1,536	112	600	964	813	1,158	357	725	902
20-29	408	693	782	408	494	848	1,111	1,142	571	905	581	851	906	474	654
30-39	389	642	473	278	438	556	660	519	334	562	444	649	494	305	484
40-49	441	761	408	402	507	561	769	690	387	592	484	764	532	394	540
50-59	484	771	687	265	524	649	914	946	296	668	542	824	816	281	577
60-64	666	1,059	724	563	714	722	916	*	745	755	685	1,002	704	621	728
65-69	691	624	*	248	665	650	1,064	*	*	723	677	812	*	404	685
70-79	873	594	*	*	845	833	274	.	*	735	863	428	*	389	816
80+	*	.	.	.	*	*	.	.	.	*
All	492	738	561	371	537	663	889	691	404	694	553	799	615	387	597
OTHER															
0-19	745	1,163	867	989	833	925	1,498	1,718	1,019	1,038	815	1,280	1,417	1,001	912
20-29	516	637	127	495	532	790	1,125	766	772	857	644	881	399	613	685
30-39	550	671	553	119	560	722	883	961	425	749	633	792	759	300	655
40-49	518	744	468	392	552	582	945	384	511	654	546	848	427	459	599
50-59	542	752	501	974	586	622	841	491	400	649	580	796	496	649	616
60-64	647	850	664	247	671	631	903	643	676	674	640	871	653	442	672
65-69	770	1,094	*	610	828	740	910	*	193	755	757	1,021	3,131	327	795
70-79	719	1,215	.	*	758	865	674	.	*	853	772	970	.	1,107	793
80+	523	*	.	.	556	*	.	.	.	*	520	*	.	.	549
All	584	801	613	551	620	694	969	910	547	742	634	883	764	549	677
ALL															
0-19	753	1,063	822	958	832	897	1,532	1,161	835	1,017	814	1,231	1,039	903	908
20-29	557	786	453	418	611	869	1,182	1,137	734	949	694	956	790	543	758
30-39	669	777	679	290	681	851	956	1,095	465	861	744	855	879	379	757
40-49	649	861	759	367	696	771	957	801	485	800	696	898	777	430	737
50-59	665	850	788	531	711	737	1,047	1,181	462	812	693	927	959	498	751
60-64	747	992	956	381	791	803	1,014	855	574	847	768	1,001	910	454	813
65-69	762	1,082	1,819	526	820	801	1,148	2,242	525	870	777	1,109	1,951	526	839
70-79	869	1,100	*	825	895	909	992	*	550	922	881	1,056	*	742	903
80+	793	337	.	.	647	*	.	.	.	*	769	337	.	.	645
All	676	865	797	442	715	807	1,040	1,067	523	854	728	936	919	481	771

* Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

On our website: counts of total admissions and years at risk used to compute total admission rates (Table E.16.1).

Table E.17
Hospital Days per Patient Year: All ESRD Patients, 1999
period prevalent patients

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	*	*	*	.	*	*	*	*	.	.	*
20-29	12.9	18.7	*	*	14.7	17.7	20.6	10.6	*	18.7	15.3	19.8	10.6	7.8	16.8
30-39	13.8	15.6	9.4	3.8	14.0	15.8	19.4	22.3	14.4	17.1	14.6	17.5	15.7	9.6	15.3
40-49	14.6	15.3	11.8	8.6	14.6	15.8	17.5	12.5	14.7	16.3	15.1	16.4	12.1	11.3	15.3
50-59	14.3	14.7	14.9	12.4	14.4	17.7	16.8	13.9	13.0	16.9	15.8	15.8	14.4	12.6	15.6
60-64	15.4	15.5	15.1	9.0	15.3	17.8	16.9	14.7	10.8	17.0	16.6	16.3	14.9	10.0	16.2
65-69	16.3	16.2	13.9	13.4	16.1	18.0	17.5	15.5	14.2	17.6	17.3	17.0	15.0	13.8	17.0
70-79	17.5	16.8	13.3	10.9	17.0	17.8	17.7	15.5	11.9	17.5	17.7	17.4	14.7	11.5	17.3
80+	18.6	18.0	18.3	12.7	18.1	18.5	19.8	16.5	13.7	18.7	18.5	19.3	17.0	13.2	18.5
All	15.7	15.7	13.9	11.1	15.5	17.6	17.5	14.8	12.8	17.3	16.6	16.8	14.4	12.0	16.5
HYPERTENSION															
0-19	9.8	3.9	.	.	6.3	10.0	4.0	.	*	6.3	9.9	4.0	.	*	6.3
20-29	5.6	5.7	*	5.1	5.6	6.8	7.8	9.8	6.7	7.5	6.1	6.4	7.4	5.6	6.3
30-39	6.4	8.0	10.3	6.2	7.6	8.3	9.2	12.9	3.5	8.9	7.1	8.4	11.1	5.2	8.0
40-49	7.8	8.7	6.9	5.9	8.5	9.2	10.4	11.1	10.5	10.2	8.3	9.3	8.3	8.0	9.0
50-59	10.1	9.3	14.7	6.9	9.6	12.9	12.5	9.0	9.5	12.4	11.1	10.5	12.5	8.2	10.6
60-64	10.5	11.4	15.7	3.8	10.9	14.1	12.9	19.4	10.3	13.3	11.9	12.1	17.9	6.3	12.0
65-69	11.4	12.0	8.1	7.7	11.5	14.1	14.4	17.4	9.9	14.1	12.5	13.3	13.1	8.9	12.8
70-79	13.1	13.9	12.8	9.8	13.2	15.0	16.6	12.8	8.4	15.5	13.9	15.6	12.8	9.1	14.3
80+	13.5	16.0	19.5	11.5	13.9	16.4	17.8	12.5	9.4	16.6	14.7	17.1	14.8	10.4	15.2
All	11.7	10.2	11.3	8.0	10.9	14.3	13.7	13.1	9.1	13.8	12.8	11.8	12.1	8.5	12.1
GLOMERULONEPHRITIS															
0-19	7.6	9.3	*	5.0	8.2	7.9	11.7	*	3.7	9.1	7.7	10.5	*	4.4	8.6
20-29	5.3	6.0	9.4	5.1	5.7	8.1	8.6	12.0	3.4	8.2	6.5	7.1	10.6	4.4	6.7
30-39	5.6	7.6	7.0	5.0	6.4	7.4	9.2	5.1	5.8	8.0	6.3	8.3	6.0	5.3	7.1
40-49	7.5	9.4	4.7	5.1	8.1	7.1	10.3	5.7	4.5	8.1	7.3	9.8	5.1	4.8	8.1
50-59	8.4	9.1	10.1	6.8	8.6	9.7	10.6	12.2	6.4	9.8	8.9	9.7	11.0	6.6	9.1
60-64	10.2	9.4	7.8	10.5	9.9	11.0	12.1	12.4	10.5	11.4	10.5	10.6	9.7	10.5	10.5
65-69	11.5	13.3	18.0	9.5	11.9	10.4	14.8	5.0	8.2	11.4	11.1	14.1	11.0	8.9	11.7
70-79	11.4	11.1	11.5	7.4	11.2	14.1	12.2	4.4	10.2	13.4	12.4	11.7	8.2	8.9	12.1
80+	12.9	19.4	*	7.9	13.3	14.4	15.9	6.0	13.3	14.5	13.5	17.5	6.2	10.6	13.8
All	8.9	9.0	8.4	6.3	8.8	10.1	10.6	7.6	6.6	10.0	9.4	9.7	8.0	6.5	9.3
OTHER															
0-19	7.1	11.1	*	8.5	8.3	7.9	14.4	5.5	8.5	9.7	7.5	12.6	6.9	8.5	8.9
20-29	6.3	7.6	4.3	5.1	6.7	9.5	13.6	9.2	10.5	11.1	7.8	10.7	7.0	8.1	8.8
30-39	7.8	10.4	14.3	9.4	8.9	8.9	12.7	7.1	9.7	10.4	8.3	11.5	10.8	9.6	9.6
40-49	8.1	10.7	8.3	6.2	9.2	9.7	13.1	7.7	9.5	11.1	8.9	11.8	8.0	8.1	10.1
50-59	8.9	10.0	11.0	9.4	9.3	10.8	12.3	15.1	12.3	11.4	9.8	11.1	13.1	11.0	10.3
60-64	11.2	12.8	9.9	9.0	11.6	12.9	13.9	9.4	13.9	13.2	12.0	13.4	9.7	11.6	12.4
65-69	11.5	14.8	15.4	9.7	12.3	13.8	15.3	19.5	13.3	14.2	12.6	15.0	17.5	11.5	13.2
70-79	12.0	12.5	15.2	9.3	12.0	13.8	18.2	10.7	12.4	14.7	12.8	15.5	12.6	11.0	13.3
80+	13.2	16.5	4.9	14.6	13.6	14.7	17.2	29.3	12.3	15.2	13.8	16.9	16.4	13.5	14.4
All	9.9	11.2	10.8	8.7	10.3	11.7	14.0	11.4	11.3	12.4	10.8	12.6	11.1	10.2	11.3
ALL															
0-19	7.3	10.1	8.4	7.1	8.2	8.1	13.3	4.9	6.2	9.7	7.6	11.6	6.2	6.7	8.8
20-29	6.6	7.1	7.1	5.0	6.8	9.9	11.6	10.6	7.2	10.5	8.1	9.1	9.0	6.0	8.5
30-39	9.0	9.4	10.1	6.1	9.1	10.5	12.0	11.3	8.1	11.1	9.6	10.5	10.7	7.1	9.9
40-49	10.3	10.4	9.0	6.2	10.2	11.3	12.9	10.5	8.7	11.9	10.7	11.3	9.7	7.5	10.9
50-59	11.4	11.1	14.1	9.6	11.3	13.9	14.3	13.6	10.6	13.9	12.5	12.6	13.8	10.1	12.5
60-64	13.0	13.2	14.1	7.8	12.9	15.5	15.2	14.8	11.2	15.2	14.1	14.3	14.5	9.5	14.1
65-69	13.5	14.3	13.7	11.1	13.7	15.8	16.2	15.3	12.4	15.8	14.6	15.4	14.7	11.8	14.8
70-79	14.0	14.6	13.3	9.8	14.0	15.9	17.1	14.1	10.9	16.1	14.9	16.2	13.8	10.4	15.1
80+	14.2	16.8	14.7	11.9	14.6	16.4	18.4	15.6	11.6	16.8	15.2	17.8	15.3	11.8	15.7
All	12.2	11.7	12.3	8.8	11.9	14.4	15.0	13.5	10.4	14.5	13.2	13.4	12.9	9.6	13.1

"." Zero patients in this cell.

* Values for cells with fewer than 10 patients are suppressed.

On our website: counts of hospital days and years at risk used to compute hospital days per patient year at risk (Table E.17.1)

Table E.18
Hospital Days per Patient Year: All ESRD Patients, 1997-1999

period prevalent patients

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	5.3	*	.	.	9.6	*	21.9	.	*	28.1	20.5	19.5	.	*	19.3
20-29	13.0	17.7	*	3.5	14.4	18.0	22.9	11.3	14.9	19.7	15.6	20.7	12.6	8.8	17.3
30-39	13.9	17.0	10.0	8.4	14.4	15.8	18.7	18.9	16.5	16.8	14.6	17.8	14.5	12.8	15.4
40-49	14.3	14.8	12.7	9.7	14.3	15.9	17.4	12.5	14.3	16.3	14.9	16.1	12.6	11.8	15.2
50-59	14.9	14.5	12.5	11.6	14.5	18.1	16.5	13.9	13.5	17.0	16.3	15.6	13.2	12.4	15.7
60-64	15.9	15.1	14.4	11.2	15.4	17.6	16.6	14.1	12.2	16.8	16.8	16.0	14.3	11.7	16.2
65-69	16.7	16.1	13.8	12.7	16.3	18.1	17.1	15.3	14.8	17.5	17.5	16.7	14.8	13.8	17.0
70-79	17.0	15.9	13.6	12.5	16.5	18.0	18.0	15.1	13.4	17.7	17.6	17.4	14.7	13.1	17.3
80+	17.9	18.5	16.3	10.4	17.5	18.6	19.4	16.2	14.9	18.7	18.3	19.2	16.2	12.8	18.3
All	15.7	15.4	13.1	11.5	15.4	17.7	17.4	14.5	13.8	17.3	16.7	16.6	13.9	12.8	16.4
HYPERTENSION															
0-19	5.8	4.0	*	.	5.0	5.4	11.2	*	*	9.2	5.6	7.0	*	*	7.0
20-29	5.3	6.5	9.3	4.8	6.2	6.1	7.6	9.3	3.2	7.0	5.6	6.9	9.3	4.3	6.5
30-39	6.6	8.0	12.7	5.0	7.7	8.1	9.1	9.4	4.7	8.8	7.1	8.4	11.6	4.9	8.0
40-49	8.1	8.6	8.6	5.3	8.5	9.7	10.0	8.0	10.3	9.9	8.6	9.1	8.4	7.5	8.9
50-59	9.7	9.4	12.5	7.7	9.5	12.5	12.2	8.3	9.1	12.1	10.7	10.4	10.7	8.4	10.5
60-64	11.8	11.1	11.7	5.7	11.2	14.2	12.4	16.4	9.2	13.0	12.7	11.7	14.3	7.2	12.0
65-69	12.3	12.5	12.1	10.1	12.3	14.9	14.3	16.2	9.5	14.4	13.4	13.4	14.3	9.7	13.3
70-79	13.4	13.4	12.2	9.4	13.2	15.6	16.0	12.2	9.5	15.5	14.3	14.9	12.2	9.5	14.3
80+	13.6	16.1	19.0	10.0	14.0	15.9	17.1	15.6	8.4	16.0	14.6	16.7	16.6	9.1	15.0
All	12.0	10.2	11.5	8.0	11.0	14.5	13.3	12.1	9.0	13.6	13.0	11.6	11.8	8.5	12.1
GLOMERULONEPHRITIS															
0-19	7.5	9.0	5.9	7.5	8.1	7.2	12.1	7.4	4.0	8.8	7.4	10.4	7.0	5.9	8.4
20-29	5.7	6.6	9.1	4.5	6.1	8.0	8.9	8.0	4.4	8.2	6.7	7.5	8.6	4.5	7.0
30-39	5.8	8.1	5.4	4.1	6.6	8.0	8.8	5.8	4.4	8.1	6.6	8.4	5.6	4.2	7.2
40-49	7.2	9.4	7.5	5.8	8.0	8.0	10.0	9.2	5.2	8.5	7.5	9.6	8.1	5.5	8.2
50-59	8.3	9.7	6.7	7.0	8.7	10.9	11.0	10.6	7.1	10.7	9.3	10.2	8.4	7.0	9.5
60-64	10.4	10.1	5.1	10.7	10.2	12.0	11.2	22.7	14.6	12.0	11.0	10.6	13.3	12.3	11.0
65-69	11.3	12.8	13.3	11.1	11.6	11.6	13.2	5.6	9.6	11.8	11.4	13.0	9.2	10.3	11.7
70-79	11.8	11.7	12.7	8.3	11.6	13.5	13.5	6.6	8.4	13.2	12.4	12.6	9.9	8.4	12.3
80+	12.7	16.1	15.2	11.5	13.1	14.5	16.5	11.1	13.4	14.7	13.5	16.3	12.9	12.4	13.8
All	8.9	9.2	8.0	6.7	8.9	10.6	10.6	8.8	6.7	10.3	9.5	9.8	8.4	6.7	9.4
OTHER															
0-19	7.8	11.5	9.5	7.8	8.7	8.8	15.3	11.8	8.2	10.5	8.2	13.1	10.9	8.0	9.4
20-29	6.6	8.3	4.5	5.7	7.1	9.5	13.3	14.9	9.3	10.9	8.0	10.9	10.0	7.6	9.0
30-39	7.5	10.2	13.7	8.4	8.6	9.7	12.3	8.3	7.6	10.6	8.5	11.2	11.1	7.9	9.6
40-49	7.9	10.5	7.7	7.2	9.0	9.6	13.5	8.0	8.9	11.1	8.7	11.9	7.9	8.1	9.9
50-59	9.6	10.5	9.1	10.3	9.9	11.0	12.8	13.7	9.6	11.6	10.3	11.6	11.3	9.9	10.7
60-64	10.5	11.9	9.5	8.3	10.8	12.4	14.3	10.2	11.1	12.9	11.4	13.1	9.9	9.6	11.9
65-69	11.7	13.3	12.8	9.0	12.0	13.9	15.1	16.9	9.2	14.1	12.8	14.2	14.9	9.1	13.1
70-79	12.5	13.1	17.0	10.3	12.6	14.4	16.6	11.2	11.3	14.8	13.4	14.9	13.7	10.8	13.6
80+	13.4	15.9	9.7	12.7	13.8	15.0	18.0	17.9	12.2	15.6	14.1	17.1	13.9	12.4	14.6
All	10.1	11.1	10.4	8.8	10.4	11.9	14.0	11.7	9.6	12.5	10.9	12.6	11.1	9.2	11.4
ALL															
0-19	7.7	10.2	8.5	7.7	8.4	8.3	14.0	11.8	6.5	10.0	8.0	11.9	10.6	7.1	9.1
20-29	6.9	7.7	8.0	4.9	7.2	10.0	11.9	10.9	6.8	10.7	8.3	9.6	9.5	5.8	8.7
30-39	9.0	9.6	10.1	5.7	9.2	11.0	11.7	10.5	7.2	11.1	9.9	10.5	10.3	6.5	10.0
40-49	10.1	10.2	10.3	6.8	10.0	11.4	12.7	10.7	8.7	11.9	10.6	11.2	10.4	7.7	10.8
50-59	11.7	11.2	11.6	9.6	11.4	14.2	14.1	13.2	10.3	14.0	12.8	12.6	12.4	9.9	12.6
60-64	13.1	12.8	13.0	9.3	12.9	15.3	14.8	14.5	11.7	14.9	14.1	13.9	13.8	10.5	13.9
65-69	13.8	14.1	13.5	11.3	13.8	16.0	15.9	15.0	12.1	15.8	14.9	15.1	14.4	11.7	14.9
70-79	14.1	14.1	13.7	10.6	14.0	16.1	16.9	13.8	11.5	16.2	15.0	15.9	13.8	11.1	15.1
80+	14.1	16.6	15.2	10.7	14.5	16.2	17.9	15.9	11.5	16.6	15.1	17.5	15.6	11.2	15.5
All	12.2	11.6	11.7	9.0	11.9	14.5	14.8	13.3	10.3	14.4	13.2	13.2	12.6	9.7	13.1

* Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

On our website: counts of hospital days and years at risk used to compute hospital days per patient year at risk (Table E.18.1).

Table E.19
Hospital Days per Patient Year : All Dialysis Patients, 1999
period prevalent patients

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	*	*	*	.	.	*	*	*	.	.	*
20-29	16.8	21.2	*	*	18.2	22.9	24.1	10.9	*	22.9	19.8	22.9	10.8	7.8	20.8
30-39	17.5	17.0	10.4	4.5	17.0	21.4	21.3	23.5	15.9	21.2	18.9	19.2	16.8	10.8	18.7
40-49	17.2	15.9	11.7	9.5	16.3	18.2	18.0	13.4	15.4	17.8	17.6	17.0	12.4	12.1	17.0
50-59	15.6	15.1	15.6	13.5	15.4	18.8	17.2	14.0	13.8	17.7	17.0	16.3	14.8	13.6	16.5
60-64	16.3	15.8	16.0	10.1	15.9	18.4	17.0	15.4	11.3	17.4	17.3	16.5	15.7	10.8	16.7
65-69	17.0	16.4	13.3	13.8	16.6	18.2	17.5	15.6	14.3	17.7	17.7	17.1	14.8	14.1	17.3
70-79	17.6	16.9	13.4	11.0	17.1	17.9	17.8	15.5	12.0	17.5	17.7	17.5	14.8	11.6	17.3
80+	18.6	18.0	18.3	12.7	18.1	18.5	19.8	16.5	13.7	18.7	18.5	19.3	17.0	13.2	18.5
All	16.9	16.1	14.3	11.7	16.4	18.4	17.8	15.1	13.1	17.8	17.7	17.2	14.7	12.5	17.2
HYPERTENSION															
0-19	*	5.2	.	.	7.7	*	4.4	.	.	6.5	*	4.8	.	.	7.2
20-29	7.3	6.0	*	6.9	6.3	7.7	8.5	10.0	7.2	8.3	7.5	6.8	7.4	7.0	7.0
30-39	7.7	8.5	7.4	7.6	8.4	10.0	9.9	13.5	4.0	9.8	8.5	9.0	9.3	6.2	8.8
40-49	8.7	9.2	7.8	7.5	9.1	10.7	11.0	11.7	13.0	11.0	9.4	9.8	9.3	9.9	9.7
50-59	11.5	9.8	15.4	7.9	10.3	14.6	13.0	8.3	11.7	13.3	12.7	11.0	12.7	9.7	11.4
60-64	11.5	11.7	15.7	4.6	11.4	14.9	13.2	19.7	11.1	13.7	12.9	12.4	18.1	7.3	12.5
65-69	12.0	12.1	8.3	7.9	11.9	14.7	14.6	17.5	10.2	14.5	13.1	13.4	13.3	9.2	13.1
70-79	13.2	13.9	12.8	9.8	13.3	15.1	16.7	12.8	8.5	15.6	14.0	15.6	12.8	9.2	14.4
80+	13.5	16.0	19.5	11.5	13.9	16.4	17.8	12.5	9.4	16.6	14.7	17.2	14.8	10.4	15.2
All	12.3	10.7	11.7	8.8	11.4	14.9	14.1	13.3	9.7	14.3	13.4	12.2	12.5	9.2	12.7
GLOMERULONEPHRITIS															
0-19	11.3	10.6	*	*	10.8	13.1	12.1	*	*	12.0	12.1	11.4	*	5.1	11.3
20-29	7.3	6.9	10.5	6.4	7.1	10.1	9.6	13.2	3.9	9.6	8.5	8.1	11.9	5.3	8.2
30-39	7.4	8.5	7.8	6.0	7.8	9.3	10.2	5.3	8.5	9.6	8.1	9.2	6.5	7.0	8.6
40-49	9.5	10.0	4.8	6.8	9.5	8.8	11.5	6.8	6.1	9.7	9.2	10.5	5.4	6.5	9.6
50-59	10.1	9.7	10.7	8.6	9.9	11.8	11.3	14.2	8.1	11.4	10.8	10.3	12.1	8.3	10.5
60-64	12.1	9.8	8.8	11.5	11.3	12.9	12.3	12.4	9.8	12.6	12.4	11.0	10.4	10.7	11.8
65-69	12.8	14.2	18.8	11.2	13.1	11.2	15.3	5.0	7.7	12.0	12.1	14.8	11.2	9.4	12.6
70-79	11.6	11.3	12.1	7.5	11.4	14.4	12.4	4.4	10.5	13.6	12.6	11.9	8.4	9.1	12.3
80+	13.0	19.4	*	7.9	13.4	14.4	15.9	6.0	13.3	14.5	13.6	17.5	6.2	10.6	13.9
All	10.5	9.7	9.0	7.6	10.1	11.8	11.5	8.3	8.1	11.4	11.0	10.5	8.7	7.8	10.6
OTHER															
0-19	12.4	13.6	*	*	12.9	11.9	18.0	*	6.2	13.9	12.2	15.7	8.3	10.7	13.3
20-29	7.7	8.3	5.6	4.5	7.8	11.7	14.5	9.8	13.3	13.0	9.6	11.6	8.0	9.7	10.4
30-39	9.5	11.2	15.4	11.9	10.4	11.3	13.9	7.4	11.5	12.5	10.3	12.5	11.5	11.7	11.4
40-49	10.0	11.2	8.8	6.7	10.5	12.1	14.2	9.7	12.0	13.0	11.0	12.5	9.1	9.6	11.6
50-59	11.0	10.5	11.8	8.9	10.7	13.1	13.2	18.9	14.2	13.3	12.0	11.8	15.1	11.9	12.0
60-64	12.9	13.5	11.2	11.0	13.0	15.1	14.0	10.7	16.2	14.7	14.0	13.8	11.0	13.7	13.9
65-69	12.1	15.1	16.1	10.4	12.8	14.7	15.5	16.3	14.3	14.9	13.4	15.3	16.2	12.4	13.9
70-79	12.1	12.4	15.2	9.4	12.1	13.9	18.1	10.7	12.4	14.8	12.9	15.4	12.6	11.1	13.4
80+	13.2	16.6	4.9	14.6	13.7	14.7	17.2	29.3	12.3	15.3	13.9	16.9	16.4	13.5	14.4
All	11.4	11.7	11.6	9.5	11.4	13.4	14.9	12.7	13.0	13.9	12.3	13.3	12.1	11.4	12.6
ALL															
0-19	12.1	12.0	*	11.3	12.0	12.6	15.4	6.5	4.9	13.4	12.3	13.7	7.3	8.0	12.6
20-29	8.5	7.9	8.2	5.7	8.1	12.3	12.8	11.4	8.8	12.4	10.2	10.1	10.0	7.3	10.0
30-39	11.4	10.2	10.4	7.5	10.6	13.4	13.1	11.8	10.3	13.1	12.2	11.4	11.1	8.8	11.7
40-49	12.4	10.9	9.4	7.6	11.4	13.5	13.7	11.8	10.9	13.5	12.8	12.0	10.4	9.2	12.2
50-59	13.1	11.7	14.9	10.7	12.4	15.9	14.9	13.9	12.3	15.2	14.3	13.2	14.4	11.5	13.7
60-64	14.3	13.5	15.0	9.0	13.8	16.7	15.3	15.5	11.9	15.9	15.4	14.5	15.3	10.5	14.9
65-69	14.3	14.5	13.4	11.7	14.2	16.3	16.4	15.2	12.7	16.2	15.3	15.6	14.5	12.2	15.3
70-79	14.2	14.7	13.4	9.9	14.1	16.0	17.2	14.1	10.9	16.2	15.0	16.2	13.8	10.5	15.2
80+	14.2	16.8	14.7	11.9	14.6	16.4	18.4	15.6	11.6	16.8	15.2	17.8	15.3	11.8	15.7
All	13.5	12.3	12.8	9.7	12.9	15.6	15.5	14.0	11.4	15.4	14.4	14.0	13.4	10.6	14.1

"." Zero patients in this cell.

* Values for cells with fewer than 10 patients are suppressed.

On our website: counts of hospital days and years at risk used to compute hospital days per patient year at risk (Table E.19.1)

Table E.20
Hospital Days per Patient Year: All Dialysis Patients, 1997-1999

period prevalent patients

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	*	*	21.9	.	*	31.3	*	23.4	.	*	27.1
20-29	15.9	19.7	*	3.5	17.1	23.1	25.8	10.3	12.5	23.8	19.6	23.3	12.7	7.2	20.8
30-39	17.7	18.5	11.1	9.0	17.6	21.6	20.5	20.2	19.3	21.0	19.1	19.5	15.8	14.5	19.0
40-49	16.9	15.4	13.1	10.1	16.0	18.5	17.8	13.3	15.5	17.9	17.5	16.6	13.2	12.6	16.9
50-59	16.0	15.0	13.1	12.5	15.4	19.1	16.8	14.3	13.8	17.7	17.4	16.0	13.7	13.1	16.5
60-64	16.7	15.4	14.9	11.9	16.0	18.0	16.7	14.5	12.8	17.1	17.4	16.2	14.7	12.4	16.6
65-69	17.2	16.2	13.7	12.9	16.6	18.3	17.2	15.1	14.9	17.6	17.8	16.8	14.6	14.0	17.2
70-79	17.2	16.0	13.8	12.7	16.6	18.0	18.0	15.1	13.4	17.8	17.6	17.4	14.7	13.1	17.3
80+	17.9	18.5	16.3	10.4	17.5	18.6	19.4	16.2	14.9	18.7	18.3	19.2	16.2	12.8	18.3
All	16.9	15.8	13.5	12.0	16.3	18.5	17.6	14.8	14.1	17.9	17.7	16.9	14.2	13.2	17.2
HYPERTENSION															
0-19	9.0	4.2	*	.	6.2	7.5	11.4	*	*	12.3	8.3	7.6	*	*	9.1
20-29	7.0	6.8	9.7	5.8	6.9	7.3	8.1	10.8	3.2	7.8	7.2	7.2	10.3	4.8	7.2
30-39	8.1	8.6	12.0	6.1	8.5	9.8	9.5	11.3	5.7	9.5	8.7	8.9	11.8	5.9	8.8
40-49	9.4	9.1	9.3	6.3	9.1	11.2	10.5	8.5	13.2	10.7	10.0	9.6	9.0	9.4	9.6
50-59	11.0	9.8	13.0	8.9	10.2	14.0	12.6	7.7	10.9	12.8	12.1	10.9	10.6	9.8	11.2
60-64	12.8	11.4	11.7	6.7	11.8	15.3	12.7	17.0	10.1	13.4	13.8	12.0	14.6	8.2	12.5
65-69	12.9	12.6	12.5	10.6	12.7	15.3	14.4	16.3	9.7	14.7	13.9	13.5	14.6	10.1	13.6
70-79	13.4	13.4	12.2	9.4	13.3	15.7	16.0	12.2	9.6	15.6	14.3	15.0	12.2	9.5	14.4
80+	13.6	16.1	19.1	10.0	14.0	15.9	17.1	15.6	8.4	16.0	14.6	16.7	16.6	9.1	15.0
All	12.6	10.7	11.9	8.7	11.5	15.1	13.6	12.5	9.7	14.1	13.6	12.0	12.2	9.2	12.6
GLOMERULONEPHRITIS															
0-19	11.5	11.2	*	10.1	11.3	11.5	13.9	10.9	4.6	12.3	11.5	12.5	10.1	7.8	11.8
20-29	8.0	7.3	9.9	5.6	7.6	10.0	9.5	8.7	5.4	9.5	8.8	8.3	9.3	5.5	8.4
30-39	7.7	8.8	6.3	5.1	8.1	10.1	9.7	6.3	5.9	9.6	8.6	9.2	6.3	5.5	8.7
40-49	9.1	9.9	8.2	7.0	9.3	9.7	10.9	10.9	6.6	10.0	9.3	10.2	9.0	6.8	9.6
50-59	10.1	10.3	7.2	8.2	10.1	12.9	11.4	12.2	8.7	12.1	11.2	10.8	9.2	8.5	10.9
60-64	12.1	10.4	6.0	12.9	11.6	13.9	11.6	22.9	13.9	13.3	12.9	10.9	15.0	13.3	12.3
65-69	12.4	13.5	14.5	11.8	12.6	12.6	13.6	5.6	9.5	12.6	12.4	13.6	9.6	10.6	12.6
70-79	11.9	11.8	13.2	8.4	11.7	13.7	13.6	6.6	8.5	13.3	12.6	12.7	10.1	8.5	12.4
80+	12.8	16.1	15.2	11.5	13.1	14.5	16.5	11.1	13.4	14.7	13.5	16.3	12.9	12.4	13.8
All	10.5	9.9	8.9	7.9	10.2	12.2	11.3	9.7	8.0	11.6	11.2	10.5	9.2	7.9	10.8
OTHER															
0-19	14.0	14.2	14.8	15.0	14.1	13.9	17.4	15.8	8.4	14.9	14.0	15.7	15.4	11.3	14.5
20-29	8.5	9.2	6.0	7.0	8.7	12.2	14.4	17.4	11.3	13.2	10.2	11.9	12.3	9.5	10.9
30-39	9.6	11.0	15.3	10.9	10.3	12.4	13.3	9.2	9.2	12.7	10.9	12.1	12.3	9.9	11.4
40-49	9.9	11.0	8.8	8.5	10.4	11.9	14.4	9.5	11.0	12.9	10.8	12.5	9.1	9.8	11.5
50-59	11.7	10.9	9.8	10.0	11.3	13.2	13.6	15.4	11.4	13.3	12.5	12.2	12.5	10.8	12.3
60-64	12.2	12.5	11.0	10.0	12.2	13.9	14.6	12.4	12.2	14.1	13.1	13.6	11.7	11.0	13.2
65-69	12.4	13.5	12.3	9.4	12.6	14.8	15.3	15.9	10.0	14.8	13.6	14.5	14.2	9.7	13.7
70-79	12.7	13.1	17.0	10.3	12.7	14.5	16.6	11.2	11.4	14.9	13.5	15.0	13.7	10.9	13.7
80+	13.5	16.0	9.7	12.7	13.8	15.0	18.1	17.9	12.2	15.6	14.1	17.1	13.9	12.4	14.6
All	11.7	11.7	11.6	9.9	11.6	13.6	14.7	12.9	10.9	13.9	12.6	13.2	12.2	10.4	12.7
ALL															
0-19	13.2	12.6	12.7	12.5	12.9	13.3	15.8	16.6	6.8	14.1	13.2	14.1	15.2	9.6	13.5
20-29	9.0	8.5	9.2	6.0	8.6	12.6	12.9	12.0	8.1	12.6	10.7	10.4	10.7	7.0	10.4
30-39	11.6	10.4	11.0	7.2	10.9	14.1	12.6	11.5	9.1	13.1	12.6	11.3	11.3	8.1	11.8
40-49	12.2	10.7	11.0	7.9	11.3	13.7	13.5	11.7	10.7	13.4	12.8	11.8	11.3	9.3	12.1
50-59	13.3	11.7	12.3	10.5	12.5	16.0	14.6	13.7	11.7	15.1	14.5	13.1	13.0	11.1	13.7
60-64	14.5	13.1	13.7	10.6	13.7	16.3	15.0	15.1	12.3	15.5	15.4	14.1	14.5	11.4	14.7
65-69	14.5	14.2	13.4	11.7	14.3	16.5	16.0	14.7	12.4	16.1	15.5	15.3	14.2	12.1	15.3
70-79	14.2	14.2	13.8	10.6	14.1	16.2	16.9	13.8	11.6	16.3	15.1	15.9	13.8	11.1	15.2
80+	14.1	16.7	15.2	10.7	14.5	16.2	17.9	15.9	11.5	16.6	15.1	17.5	15.6	11.2	15.5
All	13.5	12.2	12.4	9.9	12.9	15.7	15.2	13.8	11.3	15.3	14.5	13.7	13.1	10.6	14.1

* Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

On our website: counts of hospital days and years at risk used to compute hospital days per patient year at risk (Table E.20.1).

Table E.21
Hospital Days per Patient Year: All Hemodialysis Patients, 1999
period prevalent patients

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	*	*	*	.	.	*	*	*	.	.	*
20-29	16.2	21.5	*	*	17.9	22.1	24.9	*	*	22.9	18.9	23.5	8.8	*	20.6
30-39	17.0	17.2	9.7	4.3	16.6	21.4	21.0	21.1	12.6	20.9	18.5	19.1	15.2	8.9	18.4
40-49	17.2	15.9	11.6	9.5	16.2	17.9	17.3	12.4	15.6	17.3	17.5	16.6	12.0	12.2	16.7
50-59	15.1	14.8	15.7	13.6	15.0	18.1	17.0	13.2	14.4	17.2	16.5	16.0	14.4	14.0	16.1
60-64	15.9	15.6	16.2	10.1	15.6	18.0	16.8	15.3	11.1	17.1	17.0	16.4	15.7	10.7	16.5
65-69	16.7	16.3	13.8	14.1	16.3	17.7	17.2	15.0	13.7	17.2	17.2	16.9	14.6	13.9	16.9
70-79	17.2	16.7	14.1	11.2	16.7	17.6	17.6	15.2	11.9	17.3	17.4	17.3	14.8	11.6	17.1
80+	18.5	17.8	18.3	12.0	17.9	18.4	19.7	16.5	13.6	18.7	18.4	19.1	17.0	12.9	18.4
All	16.6	16.0	14.5	11.8	16.1	18.0	17.5	14.5	12.9	17.5	17.3	16.9	14.5	12.4	16.9
HYPERTENSION															
0-19	*	4.9	.	.	7.5	*	3.4	.	.	6.8	*	4.3	.	.	7.2
20-29	6.8	5.7	*	6.1	5.9	8.9	8.8	*	*	8.7	7.7	6.6	3.7	7.2	6.8
30-39	7.3	8.4	7.7	7.4	8.2	9.9	9.9	*	4.5	9.9	8.2	8.9	11.0	6.3	8.8
40-49	8.7	9.0	7.6	6.9	8.9	9.6	11.2	8.7	13.9	11.0	9.0	9.7	8.0	10.0	9.5
50-59	11.1	9.6	14.6	7.3	10.0	14.2	12.6	8.7	12.5	13.0	12.2	10.8	12.1	9.6	11.1
60-64	11.6	11.7	10.4	4.4	11.5	14.2	12.7	18.9	12.7	13.2	12.7	12.1	15.5	7.7	12.3
65-69	11.9	11.8	8.4	7.9	11.7	14.5	14.2	15.9	10.3	14.2	13.0	13.0	12.6	9.2	12.9
70-79	13.0	13.8	13.0	9.9	13.2	14.8	16.6	12.8	8.3	15.4	13.8	15.5	12.9	9.1	14.3
80+	13.4	16.0	19.2	11.8	13.9	16.3	17.9	13.0	9.4	16.5	14.6	17.2	15.1	10.5	15.2
All	12.3	10.6	10.9	8.7	11.3	14.7	14.1	12.9	9.9	14.2	13.3	12.1	11.9	9.3	12.5
GLOMERULONEPHRITIS															
0-19	10.7	11.1	*	*	10.8	13.7	11.7	*	*	11.4	11.8	11.4	*	6.1	11.1
20-29	7.4	6.6	11.7	4.6	7.0	9.5	8.2	17.2	3.5	8.7	8.2	7.3	14.3	4.1	7.7
30-39	7.2	8.3	7.8	5.7	7.7	9.0	9.8	6.6	5.9	9.2	7.8	8.9	7.3	5.8	8.2
40-49	9.2	9.9	5.0	6.2	9.3	8.7	11.7	5.2	7.2	9.9	9.0	10.5	5.1	6.6	9.5
50-59	9.9	9.5	11.5	8.6	9.7	11.6	10.6	15.3	8.8	11.1	10.5	9.9	13.1	8.7	10.3
60-64	11.6	9.4	10.1	11.6	10.8	12.4	11.6	12.6	10.5	12.0	11.9	10.4	11.3	11.1	11.3
65-69	12.4	13.4	18.8	8.3	12.5	11.3	15.7	4.8	6.5	12.2	11.9	14.5	11.3	7.3	12.4
70-79	11.3	11.5	8.7	7.8	11.2	14.1	12.4	4.4	10.9	13.4	12.4	12.0	6.7	9.4	12.1
80+	12.7	18.3	*	7.9	13.0	14.2	16.0	*	13.7	14.3	13.3	17.0	4.2	10.8	13.6
All	10.3	9.6	9.1	7.2	9.9	11.7	11.2	9.0	8.3	11.3	10.8	10.3	9.1	7.7	10.4
OTHER															
0-19	11.5	9.1	*	*	10.5	10.2	14.2	*	*	11.6	11.0	11.6	8.7	*	11.0
20-29	7.2	8.7	5.6	4.2	7.7	11.1	14.2	11.6	14.4	12.7	8.9	11.5	8.9	9.8	10.1
30-39	8.9	11.0	17.1	5.8	10.0	11.7	13.3	7.1	12.3	12.4	10.1	12.1	12.5	9.3	11.1
40-49	9.9	10.9	8.9	6.2	10.3	12.1	13.7	5.7	11.7	12.8	10.9	12.1	7.9	9.1	11.4
50-59	10.9	10.4	9.4	8.5	10.6	12.7	13.2	19.0	10.7	12.9	11.8	11.7	14.1	9.7	11.7
60-64	13.2	13.1	11.9	11.7	13.1	15.0	14.1	6.0	17.6	14.6	14.1	13.6	9.3	14.7	13.9
65-69	12.4	15.1	16.1	10.8	13.1	14.5	15.6	17.7	12.4	14.8	13.4	15.3	16.9	11.6	13.9
70-79	12.1	12.5	14.1	10.1	12.1	13.9	18.1	12.0	13.1	14.9	12.9	15.5	13.0	11.8	13.4
80+	13.0	16.6	*	15.4	13.6	14.7	17.4	28.3	12.3	15.3	13.8	17.0	15.3	13.9	14.3
All	11.3	11.6	11.3	9.0	11.4	13.4	14.7	12.7	12.5	13.8	12.3	13.1	11.9	10.9	12.5
ALL															
0-19	11.3	9.6	*	9.1	10.4	11.9	13.2	*	2.9	12.0	11.6	11.3	6.8	5.9	11.1
20-29	8.2	7.8	8.6	4.5	7.9	11.8	12.4	12.2	9.6	12.1	9.7	9.8	10.5	6.9	9.7
30-39	10.8	10.0	10.6	5.8	10.3	13.4	12.8	12.7	9.1	12.9	11.8	11.2	11.4	7.3	11.3
40-49	12.2	10.7	9.4	7.2	11.2	13.3	13.6	10.3	11.7	13.3	12.7	11.8	9.8	9.3	12.0
50-59	12.8	11.5	14.7	10.5	12.1	15.5	14.7	13.4	12.2	14.9	14.0	12.9	14.1	11.3	13.4
60-64	14.1	13.4	14.9	9.2	13.7	16.4	15.1	15.1	12.3	15.6	15.2	14.3	15.0	10.8	14.7
65-69	14.2	14.2	13.9	11.6	14.1	16.1	16.1	14.6	12.0	15.9	15.1	15.3	14.4	11.8	15.1
70-79	14.0	14.6	13.5	10.2	14.0	15.8	17.1	14.0	11.0	16.1	14.8	16.2	13.8	10.6	15.1
80+	14.1	16.7	14.0	11.9	14.5	16.3	18.4	15.5	11.6	16.8	15.1	17.8	15.1	11.8	15.6
All	13.3	12.1	12.9	9.6	12.7	15.5	15.4	13.6	11.4	15.3	14.3	13.8	13.3	10.5	13.9

"." Zero patients in this cell.

* Values for cells with fewer than 10 patients are suppressed.

On our website: counts of hospital days and years at risk used to compute hospital days per patient year at risk (Table E.21.1).

Table E.22
Hospital Days per Patient Year: All Hemodialysis Patients, 1997-1999

period prevalent patients

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	*	*	*	.	*	34.5	*	24.7	.	*	28.6
20-29	14.9	20.6	*	1.1	16.7	25.2	24.4	8.6	*	24.2	19.8	22.9	8.8	5.3	20.7
30-39	17.0	18.4	10.7	7.5	17.1	21.3	20.3	19.8	16.8	20.7	18.5	19.3	15.3	12.4	18.5
40-49	16.7	15.1	12.7	9.3	15.7	18.1	16.9	12.7	15.4	17.2	17.2	16.0	12.7	12.1	16.4
50-59	15.5	14.5	12.8	12.4	14.9	18.2	16.3	13.4	13.6	16.9	16.7	15.5	13.1	13.0	15.9
60-64	16.0	14.9	14.8	11.1	15.4	17.5	16.3	14.6	12.6	16.7	16.8	15.8	14.7	11.9	16.1
65-69	16.7	15.8	13.9	13.2	16.2	17.7	16.8	14.5	14.3	17.1	17.3	16.4	14.3	13.9	16.7
70-79	16.8	15.7	13.2	12.7	16.2	17.6	17.8	15.0	13.3	17.5	17.2	17.2	14.5	13.1	17.0
80+	17.7	18.3	16.1	10.3	17.3	18.4	19.4	15.8	15.1	18.6	18.1	19.1	15.9	12.8	18.1
All	16.4	15.5	13.3	11.8	15.8	18.0	17.2	14.3	13.9	17.4	17.2	16.5	13.9	12.9	16.7
HYPERTENSION															
0-19	10.1	3.8	*	.	5.9	11.9	10.8	*	.	14.8	10.8	6.7	*	.	9.6
20-29	6.4	6.6	9.7	5.9	6.6	8.1	8.1	9.3	3.4	8.0	7.1	7.0	9.5	5.2	7.0
30-39	7.8	8.4	12.1	5.4	8.3	8.7	9.2	16.3	6.6	9.1	8.1	8.7	13.0	5.8	8.6
40-49	9.3	8.8	9.5	5.6	8.9	11.1	10.4	7.1	10.3	10.4	9.9	9.3	8.7	7.6	9.4
50-59	10.4	9.5	12.7	8.8	9.8	13.4	12.2	7.8	11.7	12.4	11.5	10.5	10.5	10.0	10.7
60-64	12.5	11.2	9.3	7.0	11.5	14.6	12.4	15.1	10.1	13.0	13.3	11.8	12.4	8.3	12.2
65-69	12.4	12.2	12.4	10.0	12.3	15.2	14.1	14.6	9.6	14.3	13.6	13.2	13.6	9.8	13.3
70-79	13.2	13.3	12.0	9.4	13.1	15.3	15.8	11.8	9.4	15.3	14.1	14.8	11.8	9.4	14.2
80+	13.5	15.9	18.0	10.1	13.9	15.7	17.0	15.6	8.4	15.9	14.5	16.6	16.3	9.2	14.9
All	12.4	10.5	11.6	8.6	11.3	14.8	13.5	12.1	9.5	13.9	13.4	11.8	11.8	9.0	12.4
GLOMERULONEPHRITIS															
0-19	10.5	10.0	*	9.1	10.1	10.1	11.5	9.0	1.3	10.6	10.4	10.7	7.6	6.3	10.3
20-29	7.6	6.9	10.8	4.6	7.1	9.8	8.1	10.2	5.7	8.7	8.4	7.4	10.5	5.1	7.8
30-39	7.5	8.4	6.0	4.8	7.8	9.7	9.4	7.1	4.9	9.2	8.3	8.8	6.5	4.9	8.3
40-49	8.7	9.8	7.7	6.7	9.1	9.6	10.9	6.4	7.3	10.0	9.0	10.2	7.4	6.9	9.4
50-59	9.8	10.0	6.8	8.2	9.7	12.4	11.0	10.9	8.5	11.6	10.8	10.4	8.5	8.3	10.5
60-64	11.7	10.0	6.4	13.1	11.2	12.7	11.0	20.2	15.1	12.4	12.1	10.5	13.9	14.0	11.6
65-69	12.0	12.4	13.2	11.5	12.1	12.7	14.1	5.7	7.8	12.7	12.3	13.2	9.1	9.5	12.4
70-79	11.6	11.7	12.5	8.8	11.5	13.5	13.6	6.9	8.8	13.2	12.3	12.7	10.0	8.8	12.2
80+	12.7	15.6	14.6	11.1	12.9	14.4	16.6	10.7	14.1	14.7	13.4	16.2	12.4	12.5	13.7
All	10.2	9.6	8.5	7.7	9.9	12.1	11.1	9.2	8.2	11.4	11.0	10.2	8.8	8.0	10.5
OTHER															
0-19	12.6	11.1	9.5	22.0	12.2	12.6	13.2	7.4	9.6	12.6	12.6	12.1	8.4	14.5	12.4
20-29	8.2	8.9	6.2	7.4	8.4	11.8	14.0	12.6	12.2	12.8	9.7	11.5	9.2	10.0	10.5
30-39	9.2	10.7	17.6	8.7	10.0	12.2	12.7	10.0	8.5	12.3	10.5	11.6	14.1	8.6	11.0
40-49	9.6	10.9	8.4	7.1	10.1	11.5	13.8	8.8	11.2	12.5	10.4	12.1	8.5	9.2	11.2
50-59	11.3	10.6	8.7	9.4	10.9	12.9	13.1	15.3	10.0	12.9	12.1	11.8	11.7	9.7	11.9
60-64	12.0	12.1	12.1	10.6	12.0	13.3	14.3	10.8	13.8	13.7	12.7	13.3	11.5	12.0	12.9
65-69	12.5	13.2	12.6	9.2	12.6	14.5	14.9	15.9	10.1	14.5	13.5	14.2	14.2	9.7	13.6
70-79	12.4	13.0	15.7	9.5	12.5	14.3	16.2	12.1	11.3	14.6	13.3	14.7	13.7	10.5	13.5
80+	13.3	15.8	8.6	13.7	13.7	14.8	18.0	17.5	11.9	15.5	13.9	17.0	13.4	12.8	14.5
All	11.4	11.5	11.4	9.4	11.4	13.4	14.3	12.3	10.9	13.6	12.4	12.8	11.9	10.2	12.5
ALL															
0-19	11.9	10.2	8.4	14.3	11.2	12.4	12.6	13.3	6.5	12.3	12.1	11.3	11.4	10.4	11.7
20-29	8.5	8.1	9.1	5.6	8.2	12.7	12.3	10.5	8.9	12.3	10.3	9.9	9.8	7.1	10.0
30-39	11.0	10.1	11.3	6.1	10.4	13.6	12.2	12.7	8.6	12.7	12.0	10.9	11.9	7.2	11.3
40-49	11.9	10.5	10.7	7.2	10.9	13.4	13.1	10.7	10.7	13.1	12.5	11.5	10.7	8.8	11.8
50-59	12.9	11.4	11.9	10.4	12.0	15.5	14.2	12.9	11.5	14.6	14.0	12.7	12.4	10.9	13.2
60-64	14.0	12.8	13.5	10.4	13.3	15.8	14.7	14.7	12.6	15.1	14.9	13.8	14.2	11.5	14.3
65-69	14.2	13.8	13.6	11.6	14.0	16.2	15.6	14.1	12.0	15.8	15.2	14.9	13.9	11.8	15.0
70-79	13.9	14.0	13.2	10.6	13.8	15.9	16.7	13.8	11.5	16.0	14.9	15.7	13.6	11.1	15.0
80+	14.0	16.5	14.6	10.8	14.4	16.0	17.9	15.6	11.7	16.5	14.9	17.4	15.2	11.3	15.4
All	13.2	11.9	12.2	9.7	12.6	15.5	15.0	13.4	11.3	15.1	14.3	13.5	12.8	10.5	13.8

* Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

On our website: counts of hospital days and years at risk used to compute hospital days per patient year at risk (Table E.22.1).

Table E.23
Hospital Days per Patient Year: All CAPD/CCPD Patients, 1999
period prevalent patients

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	.	.	*	.	*	.	.	*
20-29	19.4	20.2	.	.	19.7	24.8	18.3	*	*	22.8	22.9	19.1	*	*	21.7
30-39	19.4	16.1	*	*	18.6	20.8	23.7	*	*	22.3	20.0	20.3	24.2	*	20.2
40-49	17.4	16.8	12.7	*	17.1	18.8	24.7	21.4	*	20.3	18.0	21.1	17.5	11.5	18.6
50-59	19.0	18.9	14.8	14.0	18.6	23.9	20.8	20.9	9.0	22.1	21.1	20.1	18.2	11.7	20.3
60-64	19.6	18.1	11.9	*	18.9	22.1	18.8	18.1	10.0	20.4	20.8	18.5	15.8	10.7	19.7
65-69	19.5	19.7	*	11.2	18.9	23.9	24.8	*	22.7	24.3	21.6	23.0	19.0	17.1	21.7
70-79	21.6	20.9	*	7.8	20.8	23.0	23.7	21.5	12.2	22.5	22.2	22.6	14.2	10.6	21.6
80+	21.8	*	.	*	23.6	20.1	29.3	.	*	21.2	20.9	31.0	.	23.2	22.3
All	19.5	18.7	11.4	12.0	19.0	22.3	22.4	22.5	14.7	22.1	20.8	20.9	17.8	13.5	20.5
HYPERTENSION															
0-19	*	*	.	.	*	*	*	.	.	*	*	*	.	.	*
20-29	6.6	9.5	.	*	8.5	5.3	7.0	*	*	6.9	5.8	8.5	*	6.8	7.7
30-39	10.9	9.9	*	*	10.1	10.3	9.5	*	*	9.2	10.7	9.7	*	5.5	9.7
40-49	8.1	13.6	*	10.7	11.8	15.1	9.2	*	8.2	11.1	11.0	11.6	17.0	9.6	11.5
50-59	13.8	12.7	19.6	12.1	13.3	16.1	16.7	*	9.6	16.0	14.7	14.6	16.4	10.5	14.5
60-64	10.9	11.9	*	*	11.6	18.6	17.2	*	6.2	17.3	14.5	15.3	*	6.1	14.7
65-69	12.7	20.4	*	*	14.0	15.9	23.3	*	10.9	17.9	14.1	22.0	*	9.6	15.8
70-79	14.7	17.6	*	9.1	14.8	17.5	17.6	*	11.0	17.3	15.9	17.6	*	9.8	15.9
80+	15.0	16.8	*	7.4	14.8	19.8	19.0	*	*	18.9	16.9	18.1	*	8.4	16.5
All	13.1	13.3	18.1	9.2	13.1	16.5	14.3	16.9	8.5	15.2	14.5	13.8	17.5	8.8	14.0
GLOMERULONEPHRITIS															
0-19	10.8	8.7	.	*	9.9	13.4	13.3	*	*	13.2	12.2	12.1	*	*	11.9
20-29	6.8	9.1	*	12.3	8.0	11.9	14.6	*	4.8	12.3	9.6	12.4	4.3	8.6	10.4
30-39	8.8	9.4	.	8.1	9.0	10.2	12.0	3.4	17.7	11.0	9.5	11.1	3.4	13.2	10.2
40-49	10.9	10.6	*	7.0	10.4	9.4	10.2	*	3.9	9.1	10.2	10.4	7.6	5.1	9.8
50-59	11.9	11.6	*	8.6	11.5	12.2	15.6	*	2.8	12.4	12.0	13.8	*	5.3	12.0
60-64	14.4	12.3	*	*	13.6	15.4	16.8	*	*	15.5	14.8	15.3	*	*	14.5
65-69	14.4	23.1	.	*	15.6	10.7	12.9	*	*	11.3	12.8	16.3	*	22.1	13.6
70-79	13.5	8.7	*	4.5	13.1	16.1	10.5	*	*	15.0	14.4	9.6	*	6.5	13.9
80+	15.1	*	*	.	17.3	15.6	*	*	*	15.2	15.3	*	*	*	16.4
All	11.8	11.0	8.4	9.4	11.5	12.1	12.8	5.6	6.7	11.9	11.9	12.1	6.6	8.0	11.7
OTHER															
0-19	14.0	22.0	.	*	16.4	13.3	25.1	*	*	16.7	13.7	23.4	*	*	16.6
20-29	10.4	6.4	*	*	8.9	14.1	16.4	*	10.1	14.5	12.6	12.5	*	9.0	12.3
30-39	13.0	12.7	*	40.8	13.8	10.2	17.2	*	11.2	13.2	11.5	15.6	6.6	20.8	13.4
40-49	10.1	12.3	*	8.8	10.8	12.1	16.4	17.2	13.3	13.9	11.2	14.8	13.6	11.6	12.6
50-59	10.9	10.0	*	*	11.0	14.3	13.1	*	21.6	14.2	12.8	11.9	22.6	19.8	12.9
60-64	10.5	26.0	*	*	12.5	16.3	14.4	*	*	16.2	14.0	18.1	*	*	14.7
65-69	10.8	15.0	.	*	11.2	15.4	16.3	*	*	15.9	13.2	15.6	*	19.1	13.6
70-79	12.4	8.9	*	4.2	11.9	14.3	16.6	*	5.8	13.9	13.2	12.9	*	5.0	12.8
80+	15.8	*	*	*	15.5	14.9	*	*	*	15.0	15.4	14.7	*	*	15.3
All	11.7	12.7	13.6	12.3	12.0	13.7	16.3	12.7	13.7	14.4	12.7	14.9	13.1	13.2	13.3
ALL															
0-19	13.0	19.0	.	*	14.7	13.2	19.1	*	*	15.2	13.1	19.1	*	6.7	15.0
20-29	9.6	9.2	*	10.2	9.4	14.0	14.6	9.8	6.9	13.7	12.1	12.3	8.6	8.3	11.9
30-39	14.4	11.4	8.7	18.0	13.5	13.4	14.9	9.9	14.8	14.0	13.9	13.4	9.6	16.1	13.7
40-49	13.1	13.2	9.0	8.6	12.9	14.0	14.1	18.6	8.4	13.8	13.5	13.7	14.4	8.4	13.3
50-59	15.1	14.0	16.0	12.3	14.7	17.8	17.4	18.7	9.7	17.3	16.4	15.9	17.3	10.9	16.0
60-64	15.6	16.3	16.1	8.6	15.5	19.2	17.4	21.7	8.5	18.3	17.4	17.0	19.3	8.5	17.0
65-69	15.2	19.5	6.3	12.1	15.6	18.2	22.3	27.3	20.9	19.4	16.6	21.2	17.6	16.4	17.5
70-79	16.1	17.0	12.3	7.2	15.9	18.4	19.8	15.0	10.2	18.2	17.1	18.6	14.1	8.7	16.9
80+	16.2	26.4	*	12.3	16.6	18.2	21.5	*	10.9	18.1	17.0	23.3	*	11.5	17.3
All	14.8	14.1	12.4	10.6	14.5	16.7	16.8	16.7	10.9	16.5	15.7	15.6	14.9	10.8	15.5

"." Zero patients in this cell.

* Values for cells with fewer than 10 patients are suppressed.

On our website: counts of hospital days and years at risk used to compute hospital days per patient year at risk (Table E.23.1)

Table E.24
Hospital Days per Patient Year: All CAPD/CCPD Patients, 1997-1999
period prevalent patients

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	.	.	*	.	*	.	.	*
20-29	18.0	15.0	*	*	17.5	19.0	35.1	*	*	22.8	18.6	25.8	*	*	20.6
30-39	19.3	19.8	9.1	26.6	19.3	21.7	21.4	22.1	37.3	21.9	20.3	20.7	16.6	33.3	20.5
40-49	17.6	18.2	17.1	19.7	17.7	19.6	25.4	16.6	16.0	21.0	18.4	22.1	16.8	17.5	19.2
50-59	18.8	20.4	14.2	13.1	18.8	25.0	22.8	20.6	15.9	23.8	21.5	21.8	18.0	14.2	21.2
60-64	20.4	21.0	15.7	17.9	20.4	21.6	22.1	13.7	13.3	21.2	21.0	21.6	14.5	15.4	20.8
65-69	20.3	23.3	10.8	11.0	20.2	23.2	24.3	26.5	20.3	23.5	21.7	23.9	19.3	15.7	21.9
70-79	20.3	22.0	22.0	12.9	20.4	23.3	26.4	18.8	14.8	23.5	21.7	24.7	19.9	14.1	21.9
80+	21.3	31.7	*	14.7	21.9	20.6	21.5	*	8.6	20.3	20.9	24.2	*	10.9	21.0
All	19.4	20.6	15.4	14.3	19.4	22.5	24.0	19.5	16.7	22.6	20.8	22.6	17.8	15.5	21.0
HYPERTENSION															
0-19	*	*	.	.	7.4	*	*	.	*	5.0	4.9	8.2	.	*	6.0
20-29	9.3	9.2	*	5.5	9.0	5.6	7.6	12.7	2.8	6.9	7.3	8.4	12.3	4.1	7.9
30-39	10.2	10.5	*	10.1	10.4	13.4	11.0	*	4.1	11.1	11.5	10.7	2.5	6.2	10.7
40-49	9.7	12.5	7.5	9.1	11.4	11.6	11.0	14.7	17.8	11.6	10.4	11.9	10.7	13.2	11.5
50-59	13.7	13.5	14.8	6.9	13.4	15.9	16.6	*	9.1	15.8	14.7	15.0	11.5	8.3	14.5
60-64	14.9	13.2	*	6.0	14.2	18.6	15.4	*	9.7	16.9	16.5	14.4	38.1	8.0	15.5
65-69	14.9	19.3	*	14.1	15.7	16.2	19.9	*	11.6	17.3	15.4	19.7	25.8	12.8	16.4
70-79	15.2	17.2	*	9.9	15.3	18.5	22.1	24.3	11.3	19.0	16.5	19.9	17.3	10.4	16.8
80+	14.3	24.1	*	8.6	14.8	19.0	19.9	*	6.1	18.4	16.1	21.7	*	7.4	16.3
All	14.0	13.4	13.6	9.1	13.6	16.6	15.0	16.7	10.1	15.6	15.1	14.2	15.2	9.6	14.5
GLOMERULONEPHRITIS															
0-19	12.3	14.0	*	*	12.8	12.9	17.6	*	7.0	14.3	12.6	16.1	15.4	8.9	13.6
20-29	9.4	10.4	6.0	8.9	9.6	10.6	14.2	6.7	4.7	11.5	10.1	12.5	6.4	6.7	10.7
30-39	8.7	12.1	*	6.9	9.7	11.2	10.9	4.9	8.1	10.6	10.0	11.4	5.7	7.6	10.2
40-49	10.8	10.3	10.9	7.6	10.4	10.2	10.7	21.7	5.0	10.0	10.5	10.5	15.8	6.1	10.2
50-59	11.3	13.1	10.0	8.3	11.5	13.9	13.5	*	8.6	13.4	12.5	13.3	10.2	8.5	12.4
60-64	13.6	14.1	*	13.7	13.6	18.3	14.5	*	5.4	17.2	15.6	14.4	23.9	10.0	15.3
65-69	13.4	26.9	*	13.4	14.6	12.2	10.0	*	17.1	12.1	12.9	16.8	*	15.3	13.5
70-79	13.5	12.8	*	5.4	13.3	15.2	14.9	5.3	8.7	14.8	14.1	14.0	12.2	6.6	13.9
80+	13.7	23.3	*	*	14.6	14.4	*	*	*	13.8	13.9	20.7	*	10.4	14.3
All	11.7	12.3	11.4	8.5	11.7	12.7	12.4	10.8	7.1	12.2	12.2	12.3	11.1	7.8	11.9
OTHER															
0-19	15.8	19.1	*	7.1	16.5	14.8	24.3	*	6.9	17.6	15.4	21.6	*	7.0	17.0
20-29	10.2	10.8	*	5.0	10.1	13.5	16.1	29.4	9.2	14.4	12.1	14.1	25.1	7.8	12.7
30-39	11.1	13.9	4.3	16.0	12.2	13.0	16.4	6.7	10.9	14.0	12.3	15.5	5.7	12.5	13.3
40-49	11.0	11.6	11.4	14.5	11.4	12.5	16.9	11.5	10.1	13.9	11.8	14.8	11.5	11.6	12.9
50-59	13.5	13.6	16.7	15.6	13.6	13.8	15.4	16.4	14.8	14.3	13.7	14.7	16.5	15.0	14.0
60-64	13.9	18.8	*	3.2	14.4	16.3	18.2	*	4.4	16.4	15.3	18.4	13.7	3.9	15.6
65-69	11.7	16.3	*	11.4	12.3	15.9	21.5	16.2	12.0	16.5	14.0	19.1	14.5	11.8	14.6
70-79	14.2	11.6	26.5	13.7	14.1	15.8	20.9	6.3	6.6	15.9	14.9	16.4	15.1	10.6	14.9
80+	14.5	21.7	*	0.8	14.4	16.4	11.4	*	*	15.8	15.3	16.3	*	2.9	15.0
All	12.8	13.7	12.7	12.1	13.0	14.3	17.1	15.3	10.2	14.9	13.6	15.8	14.3	10.9	14.0
ALL															
0-19	14.8	17.4	*	8.7	15.4	13.9	21.2	26.3	6.8	16.1	14.4	19.3	27.9	7.6	15.7
20-29	10.8	10.6	9.7	7.5	10.6	12.7	15.5	15.6	6.5	13.4	11.9	13.4	14.1	6.9	12.2
30-39	13.9	13.0	7.2	11.9	13.4	15.2	14.4	8.6	10.5	14.5	14.5	13.8	8.2	11.0	14.0
40-49	13.4	12.8	12.8	10.8	13.1	14.1	15.4	16.0	9.8	14.4	13.8	14.1	14.4	10.2	13.7
50-59	15.4	15.7	14.1	11.0	15.3	18.3	18.2	18.6	11.7	18.0	16.8	17.0	16.6	11.4	16.7
60-64	17.0	17.4	15.2	12.5	16.9	19.2	18.5	20.0	10.2	18.7	18.1	18.0	17.8	11.2	17.8
65-69	16.1	21.2	12.4	12.0	16.7	18.3	21.6	24.3	16.5	19.1	17.1	21.4	19.4	14.4	17.9
70-79	16.1	17.8	20.6	10.8	16.2	18.9	23.3	15.4	11.8	19.4	17.3	21.0	17.5	11.3	17.6
80+	15.2	25.0	*	9.3	15.7	18.2	19.2	*	6.4	17.8	16.5	21.6	29.9	7.9	16.6
All	15.2	15.0	14.0	10.9	14.9	17.1	17.6	16.7	10.9	16.9	16.0	16.4	15.6	10.9	15.9

* Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

On our website: counts of hospital days and years at risk used to compute hospital days per patient year at risk (Table E.24.1).

Table E.25

Hospital Days per Patient Year: All Transplant Patients, 1999*period prevalent patients; first three years after transplant*

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	.	.	.	*	*	.	.	.	*	*	.	.	.	*
20-29	5.7	9.6	.	.	6.6	8.3	6.5	*	.	7.7	7.0	7.8	*	.	7.2
30-39	6.2	8.6	*	*	6.4	7.5	9.1	*	*	7.8	6.7	8.8	9.3	4.3	7.0
40-49	6.7	9.3	12.4	2.9	7.1	8.0	9.3	1.9	10.6	8.1	7.2	9.3	7.7	6.2	7.5
50-59	6.7	8.7	6.8	5.3	7.1	6.6	9.0	13.4	2.9	7.7	6.6	8.8	9.9	4.6	7.3
60-64	7.1	9.8	1.2	0.0	7.4	6.9	12.7	1.0	5.4	8.5	7.1	11.0	1.1	2.7	7.8
65-69	4.2	11.4	*	*	6.3	10.0	10.6	*	*	10.1	6.4	11.1	*	4.8	7.8
70-79	7.3	10.3	*	*	7.6	7.3	10.6	.	*	8.6	7.3	10.4	*	*	7.9
80+	*	.	.	.	*	*	.	.	.	*
All	6.4	9.3	8.4	3.3	6.9	7.6	9.6	8.8	6.3	8.1	6.9	9.4	8.6	4.5	7.4
HYPERTENSION															
0-19	*	*	.	.	*	*	*	.	*	5.8	7.0	*	.	*	4.4
20-29	2.1	3.6	*	*	2.8	3.3	4.3	*	*	4.1	2.5	3.8	*	0.8	3.3
30-39	3.2	3.5	*	3.2	3.6	3.4	3.6	*	1.8	3.4	3.3	3.6	*	2.8	3.5
40-49	4.4	4.2	3.6	0.9	4.1	3.7	4.8	*	2.5	4.3	4.2	4.4	4.2	1.6	4.2
50-59	3.4	4.6	*	3.2	4.1	3.1	4.1	*	1.9	3.6	3.3	4.5	11.3	2.5	3.9
60-64	3.7	8.1	.	1.2	5.2	6.3	6.7	*	*	6.3	4.5	7.6	*	1.3	5.6
65-69	4.3	10.2	*	5.8	5.9	4.8	7.0	.	*	5.4	4.5	8.8	*	4.1	5.7
70-79	7.6	13.5	.	*	8.5	10.8	6.5	.	*	9.1	8.3	10.4	.	*	8.7
80+	*	*	.	.	*	*	.	.	.	*	*	*	.	.	*
All	4.1	4.8	7.7	2.6	4.4	4.4	4.8	9.5	1.9	4.5	4.2	4.8	8.3	2.3	4.5
GLOMERULONEPHRITIS															
0-19	3.0	7.2	*	*	4.7	3.7	10.7	*	*	5.5	3.4	8.7	*	3.4	5.1
20-29	2.0	2.7	*	2.9	2.3	4.5	3.7	*	2.4	4.2	3.0	3.1	3.6	2.7	3.0
30-39	2.0	3.0	*	1.8	2.2	2.9	3.7	*	0.8	3.0	2.3	3.3	3.6	1.2	2.5
40-49	2.7	5.5	*	0.9	3.2	2.6	3.0	2.6	1.1	2.5	2.6	4.5	3.2	1.0	2.9
50-59	3.8	5.0	*	0.2	3.8	2.9	5.0	*	2.0	3.2	3.5	5.0	2.8	1.2	3.6
60-64	4.2	5.6	*	7.8	4.5	3.7	8.4	.	*	4.9	4.0	6.7	*	9.8	4.6
65-69	5.4	2.9	*	1.0	4.9	4.5	7.5	.	*	5.3	5.1	4.9	*	4.5	5.0
70-79	6.8	*	*	*	6.2	2.6	*	.	*	2.4	5.7	0.8	*	*	5.1
80+	*	.	.	.	*	*	.	.	.	*
All	3.1	4.2	3.6	1.8	3.3	3.3	4.4	2.6	2.1	3.5	3.2	4.3	3.2	2.0	3.3
OTHER															
0-19	3.5	7.8	*	4.3	4.5	4.7	7.3	*	*	5.4	4.0	7.6	*	6.8	4.8
20-29	3.6	4.0	*	6.1	3.8	5.1	6.9	*	3.0	5.3	4.3	5.3	*	4.7	4.5
30-39	3.6	4.1	*	1.6	3.7	4.0	5.3	*	5.1	4.4	3.8	4.8	7.0	3.8	4.0
40-49	3.3	5.7	*	4.2	3.8	3.5	5.1	*	1.8	3.7	3.4	5.4	1.4	2.7	3.8
50-59	3.0	6.2	*	11.7	3.8	3.5	4.5	*	4.5	3.7	3.3	5.4	1.4	7.6	3.8
60-64	4.0	7.2	*	0.1	4.5	3.0	12.1	*	3.5	4.3	3.5	9.0	4.5	1.9	4.4
65-69	7.6	9.1	*	*	7.7	6.0	10.9	*	*	6.8	6.9	9.9	*	0.9	7.3
70-79	10.5	15.6	.	*	10.7	10.5	24.9	.	*	12.4	10.5	20.6	.	*	11.4
80+	*	*	.	.	*	*	*	.	.	*
All	4.0	6.0	4.6	5.1	4.4	4.2	6.3	4.9	4.0	4.6	4.1	6.1	4.8	4.4	4.5
ALL															
0-19	3.4	7.4	*	3.8	4.5	4.5	8.5	*	7.6	5.4	3.9	7.8	4.5	5.4	4.9
20-29	3.1	3.8	2.0	3.7	3.3	5.2	5.1	6.4	2.7	5.1	4.0	4.4	4.2	3.3	4.1
30-39	4.0	4.3	8.3	2.0	4.0	4.9	5.2	7.8	3.0	4.9	4.4	4.7	8.1	2.5	4.4
40-49	4.4	5.6	6.5	1.8	4.6	4.7	5.2	2.3	2.4	4.7	4.5	5.4	4.6	2.1	4.7
50-59	4.4	6.0	6.4	4.6	4.9	4.1	6.1	9.7	2.7	4.7	4.3	6.0	8.1	3.7	4.8
60-64	5.0	8.3	1.0	2.2	5.6	4.5	10.3	2.6	6.0	6.0	4.8	9.1	1.9	3.6	5.8
65-69	5.5	9.4	19.9	3.0	6.3	6.5	9.0	*	4.7	7.1	5.9	9.2	24.3	3.6	6.6
70-79	8.3	11.3	*	5.2	8.5	8.6	11.2	.	*	9.0	8.4	11.2	*	5.1	8.7
80+	5.6	*	.	.	4.3	*	.	.	.	*	5.8	*	.	.	4.5
All	4.4	5.8	6.6	3.0	4.8	4.9	6.3	6.5	3.2	5.2	4.6	6.0	6.6	3.1	4.9

" Zero patients in this cell.

* Values for cells with fewer than 10 patients are suppressed.

On our website: counts of hospital days and years at risk used to compute hospital days per patient year at risk (Table E.25.1)

Table E.26
Hospital Days per Patient Year: All Transplant Patients, 1997-1999
period prevalent patients; first three years after transplant

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	*	*	.	.	.	*	*	*	.	.	2.9
20-29	8.0	9.0	*	.	8.2	8.5	11.5	*	*	9.5	8.3	10.5	*	*	8.9
30-39	6.4	8.5	4.4	4.7	6.6	7.1	9.0	10.8	6.2	7.4	6.7	8.7	7.3	5.6	7.0
40-49	6.9	9.5	7.9	7.4	7.3	7.8	9.8	5.4	6.7	8.0	7.3	9.6	6.7	7.1	7.6
50-59	7.9	8.3	6.7	4.6	7.8	7.5	9.1	9.1	9.9	8.2	7.8	8.6	7.7	6.4	8.0
60-64	7.4	9.9	6.3	2.8	7.9	9.4	12.2	6.9	3.3	9.9	8.2	10.9	6.6	3.0	8.7
65-69	6.3	10.2	19.4	3.4	7.3	8.4	9.4	*	*	9.2	7.0	9.9	27.5	4.0	8.0
70-79	6.7	7.4	*	2.7	6.6	4.4	10.3	*	*	6.6	6.2	8.3	*	2.6	6.6
80+	*	.	.	.	*	*	.	.	.	*
All	7.1	8.9	7.2	4.8	7.4	7.7	9.9	9.6	7.1	8.2	7.3	9.3	8.3	5.7	7.7
HYPERTENSION															
0-19	2.6	3.6	*	.	3.0	4.0	*	.	*	4.8	3.4	5.4	*	*	3.9
20-29	2.1	5.0	*	2.5	3.7	3.1	5.2	*	*	4.2	2.5	5.1	3.9	2.6	3.9
30-39	3.2	3.8	*	2.5	3.6	4.0	5.7	*	2.0	4.7	3.5	4.4	10.3	2.3	3.9
40-49	3.7	4.5	5.1	1.1	4.1	4.5	5.1	3.2	1.4	4.6	3.9	4.7	4.7	1.2	4.2
50-59	4.0	4.5	8.8	3.2	4.3	4.4	5.9	16.2	1.9	5.0	4.1	5.0	11.2	2.6	4.5
60-64	5.1	6.6	*	1.5	5.5	5.9	6.7	*	2.1	6.1	5.4	6.6	*	1.7	5.7
65-69	5.1	10.2	*	4.9	6.3	4.7	8.2	.	2.7	5.8	5.0	9.3	*	4.1	6.2
70-79	7.9	11.5	.	11.4	8.7	8.9	7.5	.	*	8.3	8.2	9.9	.	9.1	8.6
80+	*	*	.	.	4.0	*	.	.	.	*	*	*	.	.	4.3
All	4.2	4.9	7.8	2.8	4.5	4.7	5.8	6.0	1.8	5.1	4.4	5.2	7.1	2.4	4.7
GLOMERULONEPHRITIS															
0-19	3.4	5.6	*	3.4	4.2	3.8	8.1	0.2	3.3	4.7	3.6	6.6	1.8	3.3	4.4
20-29	2.0	3.5	5.7	2.4	2.5	4.2	6.0	3.1	2.2	4.6	2.9	4.5	4.8	2.4	3.3
30-39	2.1	3.5	1.8	1.5	2.4	2.9	3.4	2.3	1.6	2.9	2.4	3.5	2.0	1.5	2.6
40-49	2.6	5.3	4.0	2.2	3.2	3.0	4.1	4.5	2.0	3.2	2.7	4.8	4.2	2.1	3.2
50-59	3.2	5.2	3.9	2.1	3.5	4.1	7.2	3.5	2.0	4.4	3.5	6.0	3.7	2.1	3.8
60-64	4.6	7.5	2.2	4.1	4.9	4.1	6.4	*	18.0	5.1	4.4	7.0	2.1	8.6	5.0
65-69	4.9	4.3	*	5.8	4.8	4.0	5.6	*	*	4.3	4.6	4.9	*	6.7	4.7
70-79	8.1	3.5	*	*	7.6	6.6	1.0	.	*	5.6	7.7	2.2	*	1.5	7.1
80+	*	.	.	.	*	*	.	.	.	*
All	3.0	4.5	3.5	2.3	3.3	3.6	5.1	3.0	2.6	3.9	3.2	4.8	3.3	2.4	3.5
OTHER															
0-19	3.4	7.6	2.8	3.9	4.2	4.8	10.8	8.6	8.0	5.9	3.9	8.7	6.6	5.5	4.9
20-29	3.0	3.5	0.7	3.4	3.1	4.6	7.0	3.9	3.1	5.0	3.7	5.2	2.1	3.3	4.0
30-39	3.0	3.5	4.7	0.6	3.0	3.8	5.8	3.4	2.7	4.2	3.4	4.8	4.0	1.8	3.6
40-49	3.2	5.4	1.6	2.6	3.6	3.6	6.6	1.6	2.3	4.2	3.4	6.0	1.6	2.4	3.8
50-59	3.7	6.2	5.0	11.5	4.3	4.0	5.8	5.0	2.2	4.3	3.9	6.0	5.0	6.3	4.3
60-64	3.6	6.0	3.1	0.9	3.9	4.4	9.6	2.6	6.3	5.2	3.9	7.5	2.8	3.4	4.5
65-69	6.2	8.3	*	2.8	6.6	5.7	7.8	*	1.0	5.9	6.0	8.1	22.8	1.6	6.3
70-79	7.2	11.5	.	*	7.5	7.8	16.2	.	*	8.6	7.4	13.6	.	7.3	7.9
80+	2.7	*	.	.	2.8	*	.	.	.	*	2.6	*	.	.	2.7
All	3.6	5.5	3.7	4.0	3.9	4.2	6.9	5.1	3.2	4.7	3.9	6.2	4.5	3.6	4.3
ALL															
0-19	3.4	6.7	3.4	3.7	4.2	4.4	9.7	5.8	6.1	5.5	3.8	7.8	4.9	4.8	4.7
20-29	3.1	4.3	3.1	2.8	3.4	4.9	7.0	5.6	3.1	5.4	3.9	5.4	4.3	2.9	4.3
30-39	3.9	4.4	4.8	1.7	3.9	4.8	5.7	4.8	2.5	4.9	4.3	5.0	4.8	2.1	4.4
40-49	4.4	5.6	5.1	2.8	4.7	4.9	6.0	4.0	2.4	5.0	4.6	5.8	4.7	2.6	4.8
50-59	4.9	5.9	6.4	5.0	5.2	4.9	7.1	8.1	3.3	5.5	4.9	6.4	7.1	4.2	5.3
60-64	5.1	7.6	5.2	2.3	5.6	5.8	9.3	5.2	6.8	6.7	5.4	8.3	5.2	4.0	6.0
65-69	5.7	8.9	13.8	4.4	6.3	5.8	8.1	35.9	3.0	6.3	5.7	8.6	21.0	3.9	6.3
70-79	7.5	9.5	*	6.2	7.7	7.4	9.1	*	3.9	7.7	7.5	9.3	*	5.5	7.7
80+	5.5	1.5	.	.	4.2	*	.	.	.	*	5.2	1.5	.	.	4.1
All	4.5	5.7	5.6	3.2	4.7	5.0	6.9	6.6	3.2	5.4	4.7	6.2	6.1	3.2	5.0

* Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

On our website: counts of hospital days and years at risk used to compute hospital days per patient year at risk (Table E.26.1).

Table E.27

Total Hospital Discharges by General Diagnostic Related Group*period prevalent patients, 1997-1999*

ALL PATIENTS	1997			1998			1999		
	Medical	Procedure	All	Medical	Procedure	All	Medical	Procedure	All
Nervous system	21,028	2,599	23,627	21,968	2,833	24,801	22,559	2,828	25,387
Eye	262	485	747	288	454	742	291	372	663
ENT	1,505	244	1,749	1,723	267	1,990	2,037	220	2,257
Respiratory system	32,652	1,519	34,171	34,416	1,646	36,062	37,233	1,781	39,014
Circulatory system	92,603	80,971	173,574	98,420	79,151	177,571	103,779	79,212	182,991
GI system	30,160	8,269	38,429	31,350	7,886	39,236	31,518	7,622	39,140
Hepatic system	6,693	2,898	9,591	6,709	2,905	9,614	6,859	2,938	9,797
Muscular/skeletal system	8,447	9,943	18,390	8,906	10,483	19,389	9,795	10,953	20,748
Skin/breast	5,499	2,925	8,424	6,197	3,073	9,270	6,813	3,165	9,978
Endocrine system	17,766	4,130	21,896	18,230	3,998	22,228	19,198	4,233	23,431
Renal system	47,654	29,343	76,997	48,219	27,745	75,964	48,673	26,325	74,998
Male reproduction system	277	728	1,005	349	667	1,016	340	679	1,019
Female reproduction system	341	861	1,202	389	846	1,235	411	763	1,174
Pregnancy	137	84	221	156	81	237	198	82	280
Hematologic system	3,585	268	3,853	3,911	252	4,163	3,942	224	4,166
Myeloproliferative system	1,264	325	1,589	1,343	314	1,657	1,300	317	1,617
Infection	22,000	5,961	27,961	21,989	5,669	27,658	21,618	5,091	26,709
Psych	5,316	317	5,633	5,138	277	5,415	5,335	261	5,596
Injury/poisoning	6,608	4,505	11,113	6,650	4,619	11,269	6,933	4,471	11,404
Burns	81	68	149	55	65	120	.	2	2
Other factors	9,775	902	10,677	11,029	953	11,982	13,020	1,067	14,087
Unclassified	.	3,402	3,402	.	3,605	3,605	.	4,513	4,513
HIV	1,723	237	1,960	1,693	172	1,865	1,840	191	2,031
All	315,376	160,984	476,360	329,128	157,961	487,089	343,692	157,310	501,002
ALL DIALYSIS									
Nervous system	18,596	2,211	20,807	19,531	2,399	21,930	19,944	2,441	22,385
Eye	203	410	613	231	391	622	227	310	537
ENT	1,052	167	1,219	1,212	187	1,399	1,384	138	1,522
Respiratory system	29,028	1,218	30,246	30,398	1,325	31,723	32,343	1,435	33,778
Circulatory system	85,815	77,055	162,870	91,063	75,151	166,214	95,814	74,850	170,664
GI system	26,528	7,251	33,779	27,472	6,725	34,197	27,218	6,462	33,680
Hepatic system	5,337	2,205	7,542	5,372	2,278	7,650	5,449	2,298	7,747
Muscular/skeletal system	7,167	7,891	15,058	7,615	8,374	15,989	8,277	8,843	17,120
Skin/breast	4,301	2,426	6,727	4,883	2,572	7,455	5,425	2,644	8,069
Endocrine system	14,195	3,561	17,756	14,528	3,427	17,955	15,177	3,617	18,794
Renal system	37,073	18,451	55,524	37,455	16,917	54,372	37,671	15,804	53,475
Male reproduction system	205	547	752	262	520	782	252	505	757
Female reproduction system	260	609	869	288	595	883	318	511	829
Pregnancy	46	30	76	56	27	83	89	36	125
Hematologic system	2,885	145	3,030	3,186	134	3,320	3,189	135	3,324
Myeloproliferative system	1,093	230	1,323	1,095	240	1,335	1,090	214	1,304
Infection	18,413	5,234	23,647	18,506	4,962	23,468	18,063	4,440	22,503
Psych	4,637	307	4,944	4,479	268	4,747	4,622	255	4,877
Injury/poisoning	5,995	4,108	10,103	6,036	4,139	10,175	6,177	4,023	10,200
Burns	71	58	129	45	52	97	.	1	1
Other factors	8,580	839	9,419	9,721	893	10,614	11,493	979	12,472
Unclassified	.	2,900	2,900	.	3,105	3,105	.	3,805	3,805
HIV	1,705	237	1,942	1,646	170	1,816	1,755	188	1,943
All	273,185	138,090	411,275	285,080	134,851	419,931	295,977	133,934	429,911

." Zero patients in this cell.
One DRG per discharge.

Table E.27 (continued)

Total Hospital Discharges by General Diagnostic Related Group

period prevalent patients, 1997-1999

HEMODIALYSIS	1997			1998			1999		
	Medical	Procedure	All	Medical	Procedure	All	Medical	Procedure	All
Nervous system	14,288	1,701	15,989	15,753	1,971	17,724	17,335	2,177	19,512
Eye	162	339	501	187	342	529	200	275	475
ENT	857	139	996	1,038	156	1,194	1,242	125	1,367
Respiratory system	23,714	960	24,674	25,769	1,097	26,866	29,561	1,307	30,868
Circulatory system	67,030	63,434	130,464	75,628	64,821	140,449	87,537	69,827	157,364
GI system	18,448	4,830	23,278	20,221	4,806	25,027	22,159	5,144	27,303
Hepatic system	4,104	1,733	5,837	4,354	1,852	6,206	4,815	2,005	6,820
Muscular/skeletal system	5,777	6,455	12,232	6,497	7,120	13,617	7,608	8,080	15,688
Skin/breast	3,442	1,928	5,370	4,095	2,181	6,276	4,919	2,400	7,319
Endocrine system	10,367	2,777	13,144	11,319	2,870	14,189	12,934	3,219	16,153
Renal system	24,844	9,902	34,746	28,226	11,396	39,622	33,277	13,479	46,756
Male reproduction system	162	412	574	205	419	624	221	451	672
Female reproduction system	187	473	660	221	460	681	264	440	704
Pregnancy	38	28	66	48	25	73	82	32	114
Hematologic system	2,197	113	2,310	2,509	118	2,627	2,755	122	2,877
Myeloproliferative system	762	150	912	812	178	990	934	193	1,127
Infection	14,278	4,061	18,339	15,206	4,079	19,285	16,196	3,966	20,162
Psych	3,828	243	4,071	3,798	219	4,017	4,259	219	4,478
Injury/poisoning	2,669	1,718	4,387	2,959	1,840	4,799	3,364	1,940	5,304
Burns	65	43	108	38	46	84	.	1	1
Other factors	6,243	628	6,871	7,764	727	8,491	10,290	885	11,175
Unclassified	.	1,951	1,951	.	2,415	2,415	.	3,259	3,259
HIV	1,387	169	1,556	1,400	128	1,528	1,554	167	1,721
All	204,849	104,187	309,036	228,047	109,266	337,313	261,506	119,713	381,219
PERITONEAL DIALYSIS									
Nervous system	2,523	280	2,803	2,346	258	2,604	2,129	220	2,349
Eye	26	41	67	26	31	57	22	30	52
ENT	104	15	119	104	23	127	122	12	134
Respiratory system	2,166	117	2,283	2,089	93	2,182	2,049	91	2,140
Circulatory system	7,251	4,812	12,063	6,678	4,299	10,977	5,941	3,843	9,784
GI system	5,682	1,544	7,226	5,440	1,350	6,790	4,487	1,141	5,628
Hepatic system	737	278	1,015	706	284	990	502	248	750
Muscular/skeletal system	682	835	1,517	589	723	1,312	530	632	1,162
Skin/breast	444	286	730	412	228	640	418	203	621
Endocrine system	2,450	389	2,839	2,226	300	2,526	1,927	343	2,270
Renal system	3,368	1,691	5,059	3,091	1,451	4,542	2,774	1,422	4,196
Male reproduction system	23	61	84	38	43	81	28	44	72
Female reproduction system	47	94	141	42	95	137	45	59	104
Pregnancy	6	1	7	6	1	7	7	3	10
Hematologic system	339	19	358	383	8	391	365	11	376
Myeloproliferative system	87	13	100	53	13	66	65	8	73
Infection	1,831	504	2,335	1,655	419	2,074	1,318	354	1,672
Psych	401	30	431	388	25	413	292	29	321
Injury/poisoning	2,780	2,041	4,821	2,699	2,015	4,714	2,633	1,944	4,577
Burns	4	12	16	4	4	8	.	.	.
Other factors	914	58	972	976	77	1,053	955	79	1,034
Unclassified	.	420	420	.	366	366	.	429	429
HIV	194	28	222	150	19	169	178	16	194
All	32,059	13,569	45,628	30,101	12,125	42,226	26,787	11,161	37,948

." Zero patients in this cell.

Table E.27 (continued)

Total Hospital Discharges by General Diagnostic Related Group*period prevalent patients, 1997-1999*

TRANSPLANT	1997			1998			1999		
	Medical	Procedure	All	Medical	Procedure	All	Medical	Procedure	All
Nervous system	1,862	303	2,165	1,876	317	2,193	1,895	285	2,180
Eye	49	63	112	42	51	93	48	46	94
ENT	361	62	423	425	69	494	545	65	610
Respiratory system	2,655	238	2,893	3,086	245	3,331	3,625	264	3,889
Circulatory system	4,787	2,792	7,579	5,069	2,838	7,907	5,221	2,805	8,026
GI system	2,584	724	3,308	2,753	829	3,582	3,011	789	3,800
Hepatic system	1,033	533	1,566	1,043	491	1,534	1,073	482	1,555
Muscular/skeletal system	1,052	1,728	2,780	1,015	1,785	2,800	1,166	1,691	2,857
Skin/breast	1,002	416	1,418	1,120	418	1,538	1,136	420	1,556
Endocrine system	2,674	472	3,146	2,825	466	3,291	2,986	501	3,487
Renal system	6,927	2,339	9,266	7,287	2,509	9,796	7,667	2,558	10,225
Male reproduction system	53	130	183	61	98	159	65	121	186
Female reproduction system	65	207	272	86	209	295	65	207	272
Pregnancy	74	47	121	80	48	128	93	31	124
Hematologic system	446	58	504	477	39	516	493	41	534
Myeloproliferative system	139	78	217	209	70	279	179	93	272
Infection	2,587	455	3,042	2,536	456	2,992	2,546	414	2,960
Psych	475	5	480	450	5	455	484	3	487
Injury/poisoning	372	198	570	382	250	632	450	221	671
Burns	9	7	16	10	11	21	.	.	.
Other factors	832	41	873	939	43	982	1,078	57	1,135
Unclassified	.	345	345	.	357	357	.	498	498
HIV	6	.	6	8	.	8	5	1	6
All	30,044	11,241	41,285	31,779	11,604	43,383	33,831	11,593	45,424

"." Zero patients in this cell.

